US20210378982A1 - Fullerenes to treat diseases and conditions - Google Patents
Fullerenes to treat diseases and conditions Download PDFInfo
- Publication number
- US20210378982A1 US20210378982A1 US17/277,099 US201917277099A US2021378982A1 US 20210378982 A1 US20210378982 A1 US 20210378982A1 US 201917277099 A US201917277099 A US 201917277099A US 2021378982 A1 US2021378982 A1 US 2021378982A1
- Authority
- US
- United States
- Prior art keywords
- fullerenes
- composition
- phf
- product
- food product
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- XMWRBQBLMFGWIX-UHFFFAOYSA-N C60 fullerene Chemical class C12=C3C(C4=C56)=C7C8=C5C5=C9C%10=C6C6=C4C1=C1C4=C6C6=C%10C%10=C9C9=C%11C5=C8C5=C8C7=C3C3=C7C2=C1C1=C2C4=C6C4=C%10C6=C9C9=C%11C5=C5C8=C3C3=C7C1=C1C2=C4C6=C2C9=C5C3=C12 XMWRBQBLMFGWIX-UHFFFAOYSA-N 0.000 title claims abstract description 119
- 229910003472 fullerene Inorganic materials 0.000 title claims abstract description 118
- 201000010099 disease Diseases 0.000 title claims abstract description 30
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 30
- 239000000203 mixture Substances 0.000 claims abstract description 55
- 238000000034 method Methods 0.000 claims abstract description 32
- 206010061218 Inflammation Diseases 0.000 claims abstract description 6
- 230000004054 inflammatory process Effects 0.000 claims abstract description 6
- 238000004519 manufacturing process Methods 0.000 claims description 54
- 235000013305 food Nutrition 0.000 claims description 33
- 150000001875 compounds Chemical class 0.000 claims description 22
- 239000007788 liquid Substances 0.000 claims description 17
- 239000000843 powder Substances 0.000 claims description 14
- 239000003925 fat Substances 0.000 claims description 12
- 235000019197 fats Nutrition 0.000 claims description 11
- 239000000499 gel Substances 0.000 claims description 10
- 235000013351 cheese Nutrition 0.000 claims description 8
- 235000018102 proteins Nutrition 0.000 claims description 8
- 102000004169 proteins and genes Human genes 0.000 claims description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 8
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 7
- 125000004432 carbon atom Chemical group C* 0.000 claims description 7
- 229910052717 sulfur Inorganic materials 0.000 claims description 7
- 239000011593 sulfur Substances 0.000 claims description 7
- 239000006071 cream Substances 0.000 claims description 6
- 239000000839 emulsion Substances 0.000 claims description 5
- 208000024891 symptom Diseases 0.000 claims description 5
- 235000015173 baked goods and baking mixes Nutrition 0.000 claims description 4
- 235000014121 butter Nutrition 0.000 claims description 4
- 150000001720 carbohydrates Chemical class 0.000 claims description 4
- 235000014633 carbohydrates Nutrition 0.000 claims description 4
- 235000019219 chocolate Nutrition 0.000 claims description 4
- 239000012141 concentrate Substances 0.000 claims description 4
- 235000020186 condensed milk Nutrition 0.000 claims description 4
- 235000014048 cultured milk product Nutrition 0.000 claims description 4
- 235000013365 dairy product Nutrition 0.000 claims description 4
- 235000021185 dessert Nutrition 0.000 claims description 4
- 235000019541 flavored milk drink Nutrition 0.000 claims description 4
- 235000020351 fruit smoothie Nutrition 0.000 claims description 4
- 235000015243 ice cream Nutrition 0.000 claims description 4
- 235000015110 jellies Nutrition 0.000 claims description 4
- 239000008274 jelly Substances 0.000 claims description 4
- 235000004213 low-fat Nutrition 0.000 claims description 4
- 235000013310 margarine Nutrition 0.000 claims description 4
- 239000003264 margarine Substances 0.000 claims description 4
- 239000008268 mayonnaise Substances 0.000 claims description 4
- 235000010746 mayonnaise Nutrition 0.000 claims description 4
- 235000014059 processed cheese Nutrition 0.000 claims description 4
- 235000011962 puddings Nutrition 0.000 claims description 4
- 235000013570 smoothie Nutrition 0.000 claims description 4
- 239000007921 spray Substances 0.000 claims description 4
- 235000013618 yogurt Nutrition 0.000 claims description 4
- 229910052768 actinide Inorganic materials 0.000 claims description 3
- 150000001255 actinides Chemical class 0.000 claims description 3
- 229910052783 alkali metal Inorganic materials 0.000 claims description 3
- 150000001340 alkali metals Chemical class 0.000 claims description 3
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims description 3
- 150000001342 alkaline earth metals Chemical class 0.000 claims description 3
- 238000000338 in vitro Methods 0.000 claims description 3
- 229910052747 lanthanoid Inorganic materials 0.000 claims description 3
- 150000002602 lanthanoids Chemical class 0.000 claims description 3
- 229910001848 post-transition metal Inorganic materials 0.000 claims description 3
- 150000003573 thiols Chemical class 0.000 claims description 3
- 229910052723 transition metal Inorganic materials 0.000 claims description 3
- 150000003624 transition metals Chemical class 0.000 claims description 3
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 104
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 98
- 239000011734 sodium Substances 0.000 description 68
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 52
- 239000011589 pyridoxal 5'-phosphate Substances 0.000 description 44
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 43
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 description 43
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 35
- 235000018417 cysteine Nutrition 0.000 description 35
- 241000699670 Mus sp. Species 0.000 description 23
- 108010045283 Cystathionine gamma-lyase Proteins 0.000 description 19
- 238000005516 engineering process Methods 0.000 description 18
- 102100035429 Cystathionine gamma-lyase Human genes 0.000 description 14
- 229940046892 lead acetate Drugs 0.000 description 14
- 239000000758 substrate Substances 0.000 description 14
- 230000003197 catalytic effect Effects 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 12
- 206010019280 Heart failures Diseases 0.000 description 10
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 238000001727 in vivo Methods 0.000 description 10
- 238000007792 addition Methods 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 229940056932 lead sulfide Drugs 0.000 description 9
- 229910052981 lead sulfide Inorganic materials 0.000 description 9
- 239000004201 L-cysteine Substances 0.000 description 8
- 235000013878 L-cysteine Nutrition 0.000 description 8
- 239000003054 catalyst Substances 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 125000000524 functional group Chemical group 0.000 description 8
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 8
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 8
- 235000005911 diet Nutrition 0.000 description 7
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 6
- 229960004308 acetylcysteine Drugs 0.000 description 6
- 239000013543 active substance Substances 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 206010007558 Cardiac failure chronic Diseases 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 230000037213 diet Effects 0.000 description 5
- 230000002526 effect on cardiovascular system Effects 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 210000005240 left ventricle Anatomy 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 208000024827 Alzheimer disease Diseases 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 4
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 4
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 230000032683 aging Effects 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 229930182817 methionine Natural products 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- 235000019158 vitamin B6 Nutrition 0.000 description 4
- 239000011726 vitamin B6 Substances 0.000 description 4
- 229940011671 vitamin b6 Drugs 0.000 description 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 238000004833 X-ray photoelectron spectroscopy Methods 0.000 description 3
- 210000001789 adipocyte Anatomy 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 235000009200 high fat diet Nutrition 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 238000011813 knockout mouse model Methods 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- 230000004962 physiological condition Effects 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010007556 Cardiac failure acute Diseases 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 108010073644 Cystathionine beta-synthase Proteins 0.000 description 2
- 102000020018 Cystathionine gamma-Lyase Human genes 0.000 description 2
- 208000032928 Dyslipidaemia Diseases 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 208000010228 Erectile Dysfunction Diseases 0.000 description 2
- 229920003134 Eudragit® polymer Polymers 0.000 description 2
- 229910052688 Gadolinium Inorganic materials 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 208000017170 Lipid metabolism disease Diseases 0.000 description 2
- 125000003047 N-acetyl group Chemical group 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 208000022873 Ocular disease Diseases 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000006555 catalytic reaction Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 230000001934 delay Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000007933 dermal patch Substances 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000000890 drug combination Substances 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 239000003889 eye drop Substances 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 238000002173 high-resolution transmission electron microscopy Methods 0.000 description 2
- 201000001881 impotence Diseases 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 239000007922 nasal spray Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229940000673 orphan drug Drugs 0.000 description 2
- 239000002859 orphan drug Substances 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 208000030613 peripheral artery disease Diseases 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 229960003581 pyridoxal Drugs 0.000 description 2
- 235000008164 pyridoxal Nutrition 0.000 description 2
- 239000011674 pyridoxal Substances 0.000 description 2
- 229940107700 pyruvic acid Drugs 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 208000013220 shortness of breath Diseases 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- HYHCSLBZRBJJCH-UHFFFAOYSA-M sodium hydrosulfide Chemical compound [Na+].[SH-] HYHCSLBZRBJJCH-UHFFFAOYSA-M 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- 230000003867 tiredness Effects 0.000 description 2
- 208000016255 tiredness Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000010936 titanium Substances 0.000 description 2
- 229910052719 titanium Inorganic materials 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000003932 viscosupplement Substances 0.000 description 2
- AOITVOSSTJRHSS-UHFFFAOYSA-N (c{60}-i{h})[5,6]fullerane-1,2,3,4,5,7,13,23,24,27,29,32,35,36,39,40,42,44,49,50,53,55,56,58-tetracosol Chemical compound OC12C3C4C(O)(C56O)C7(O)C1C(C18O)(O)C9C2(O)C2C(C%10C%11(C(C%12(C(O)(C%13%14)C%15%11O)O)(O)C%11%16)O)C3C%15C4C%14C5C3C%13C(C4C5(O)C%13%14)(O)C%12C5C%11C5C%13(O)C%11C%12(O)C%13(O)C5C%16C%10(O)C2C%13(O)C9(O)C%12C8C2(O)C(C58O)C1C7C6C8(O)C3(O)C4C5C%14C2%11 AOITVOSSTJRHSS-UHFFFAOYSA-N 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 206010000117 Abnormal behaviour Diseases 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010011778 Cystinuria Diseases 0.000 description 1
- 206010052337 Diastolic dysfunction Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020365 Homocystinuria Diseases 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 208000033892 Hyperhomocysteinemia Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000005764 Peripheral Arterial Disease Diseases 0.000 description 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 102100038803 Somatotropin Human genes 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 208000037883 airway inflammation Diseases 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 229910003481 amorphous carbon Inorganic materials 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 244000144987 brood Species 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 108010076637 carbon-sulfur lyase Proteins 0.000 description 1
- 102000028406 carbon-sulfur lyase Human genes 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- CETPSERCERDGAM-UHFFFAOYSA-N ceric oxide Chemical compound O=[Ce]=O CETPSERCERDGAM-UHFFFAOYSA-N 0.000 description 1
- 229910000422 cerium(IV) oxide Inorganic materials 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 230000006999 cognitive decline Effects 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000036576 dermal application Effects 0.000 description 1
- 229960002069 diamorphine Drugs 0.000 description 1
- 235000020805 dietary restrictions Nutrition 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 125000002228 disulfide group Chemical group 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000010410 dusting Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000008387 emulsifying waxe Substances 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 238000012226 gene silencing method Methods 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000007446 glucose tolerance test Methods 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000003225 hyperhomocysteinemia Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000006372 lipid accumulation Effects 0.000 description 1
- -1 liquid paraffin Polymers 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
- 239000002086 nanomaterial Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 231100000878 neurological injury Toxicity 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000012053 oil suspension Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 210000003899 penis Anatomy 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 201000002793 renal fibrosis Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 201000002859 sleep apnea Diseases 0.000 description 1
- 230000003997 social interaction Effects 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000019086 sulfide ion homeostasis Effects 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- MHXBHWLGRWOABW-UHFFFAOYSA-N tetradecyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCC MHXBHWLGRWOABW-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000006438 vascular health Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 210000004127 vitreous body Anatomy 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
- C01B32/00—Carbon; Compounds thereof
- C01B32/15—Nano-sized carbon materials
- C01B32/152—Fullerenes
- C01B32/156—After-treatment
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/44—Elemental carbon, e.g. charcoal, carbon black
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
- C01B32/00—Carbon; Compounds thereof
- C01B32/15—Nano-sized carbon materials
- C01B32/152—Fullerenes
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/25—Animals on a special diet
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0362—Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Definitions
- compositions, systems, kits, and methods for treating a subject with a disease or condition by administering a composition comprising fullerenes to the subject such that H2S is generated in said subject.
- the disease or condition is associated with inflammation and/or below normal H2S levels.
- the fullerenes are polyhydroxy fullerenes (PHFs).
- H2S hydrogen sulfide
- CBS cystathionine ⁇ -synthase
- CGL cystathionine ⁇ -lyase
- H2S endogenous hypothalamic sarcoma
- aging Huang et al., 2015; Yang et al., 2008
- cardiovascular Kovacic et al., 2012
- metabolic Szabo, 2012
- neurodegenerative disorders Huang et al., 2014
- Exposure to supra-physiological levels of H2S can be beneficial.
- H2S increases vasodilation of blood vessels and lowers blood pressure (Zhao et al., 2001), protects against ischemia reperfusion injury to multiple organs including heart (Elrod et al., 2007) and liver (Jha et al., 2008), improves insulin sensitivity and/or responses to glucose (Suzuki et al., 2011; Xue et al., 2013), delays cognitive decline in animal models of Alzheimer's disease (Giuliani et al., 2013), and is associated or causative of extended longevity (Hine et al., 2015).
- H2S supplementation is conceptually the most straightforward, with multiple different forms of H2S already available, from the short-acting gas itself (Blackstone et al., 2005) to short- and long-lasting chemical H2S donors (Alves et al., 2011; Polhemus et al., 2015).
- this approach risks acute toxicity, so that targeted delivery to the proper organ and cell type at the optimal dose may be challenging to achieve.
- compositions, systems, kits, and methods for treating a subject with a disease or condition by administering a composition comprising fullerenes to the subject such that H2S is generated in said subject.
- the disease or condition is associated with inflammation and/or below normal H2S levels.
- the fullerenes are polyhydroxy fullerenes (PHFs).
- kits for treating a subject with a disease or condition comprising: administering a composition comprising fullerenes to said subject with said disease or condition (e.g., such that H2S is generated in said subject).
- the disease or condition is associated with inflammation and/or below normal H2S levels in said subject.
- the administering reduces or eliminates at least one symptom of said disease or condition.
- the fullerenes comprise polyhydroxy fullerenes. In certain embodiments, the fullerenes in said composition are all one type of fullerene. In further embodiments, the fullerenes in the composition are two or more types of fullerenes.
- the fullerenes in the composition are all one type of fullerene selected from the group consisting of: C 60 (OH) 9 O 7 Na 6 ; C 60 (OH) 11 O 8 Na 5 ; C 60 (OH) 11 O 12 Na 8 ; C 60 (OH) 11 O 20 Na 10 K 6 ; C 60 (OH) 6 O 4 Na 4 ; C 60 (OH) 20 O 8 Na 4 ; C 60 (OH) 10 O 13 Na 6 ; C 60 (OH) 4 O 14 Na 17 ; C 60 (OH) 13 O 4 Na 3 ; C 60 (OH) 10 ; C 60 (OH) 22-24 ; C 60 (OH) 36 ; C 60 (OH) 44 ; C 60 O 13 Na 14 ; Gd@C 82 (OH) 15 O 12 Na 5 ; Gd 3 N@C 80 (OH) 13 O 9 Na 6 ; C 60 (OH) 11 O 8 S 8 Na 5 ; C 60 (OH) 11 (SH) 5 O 8 Na 5 ; C 60 C 12 N 4 H 24 ;
- the fullerenes in said composition are two or more types of fullerenes selected from the group consisting of: C 60 (OH) 9 O 7 Na 6 ; C 60 (OH) 11 O 8 Na 5 ; C 60 (OH) 11 O 12 Na 8 ; C 60 (OH) 11 O 20 Na 10 K 6 ; C 60 (OH) 6 O 4 Na 4 ; C 60 (OH) 20 O 8 Na 4 ; C 60 (OH) 10 O 13 Na 6 ; C 60 (OH) 4 O 14 Na 17 ; C 60 (OH) 13 O 4 Na 3 ; C 60 (OH) 10 ; C 60 (OH) 22-24 ; C 60 (OH) 36 ; C 60 (OH) 44 ; C 60 O 13 Na 14 ; Gd@C 82 (OH) 15 O 12 Na 5 ; Gd 3 N@C 80 (OH) 13 O 9 Na 6 ; C 60 (OH) 11 O 8 S 8 Na 5 ; C 60 (OH) 11 (SH) 5 O 8 Na 5 ; C 60 C 12 N 4 H 24
- the fullerenes are one or more compounds according to the formula C 2n (OH) t (SH) u (NH 2 ) v (COOH) w (COOM) x O y M z , wherein M is an alkali metal, alkaline earth metal, transition metal, post-transition metal, lanthanide or actinide, n is a number ranging from 10 to 270; and t, u, v, w, x, y and z can range from 0 to the total number of carbon atoms present in the cage.
- the composition comprises a food product.
- the food product comprises carbohydrates, proteins, and fats.
- the food product is in a form selected from the group consisting of: mayonnaise, margarine, low fat spread, yoghurt, a fruit smoothie, a beverage, a protein smoothie, a cheese spread, processed cheese, a dairy dessert, a flavored milk, cream, a fermented milk product, cheese, butter, a condensed milk product, an ice cream mix, a soy product, pasteurized liquid egg, a bakery product, a confectionary product, confectionary bar, chocolate bar, high fat bar, energy bar, liquid emulsion, powder, spray dried powder, freeze dried powder, pudding, a gel, a gel concentrate, a liquid drink, and jelly.
- said composition is located in a skin patch or eye drop solution.
- the methods further comprise capturing at least some of said H2S that is generated.
- the capture H2S is stored.
- the fullerenes are used in various biotechnology methods for processing amino acids.
- compositions or articles of manufacture comprising: a food product, wherein said food product comprises a composition comprising fullerenes.
- the food product comprises carbohydrates, proteins, and fats.
- the food product is in a form selected from the group consisting of: mayonnaise, margarine, low fat spread, yoghurt, a fruit smoothie, a protein smoothie, a cheese spread, processed cheese, a dairy dessert, a flavored milk, cream, a fermented milk product, cheese, butter, a condensed milk product, an ice cream mix, a soy product, pasteurized liquid egg, a bakery product, a confectionary product, confectionary bar, chocolate bar, high fat bar, energy bar, liquid emulsion, powder, spray dried powder, freeze dried powder, pudding, a gel, a gel concentrate, a liquid drink, and jelly.
- the food product qualifies as a medical food as defined in the Orphan Drug Act.
- the fullerenes in the food product comprise polyhydroxy fullerenes. In additional embodiments, the fullerenes in said food product are all one type of fullerene. In other embodiments, the fullerenes in the food production are two or more types of fullerenes.
- the fullerenes in the food product are all one type of fullerene selected from the group consisting of: C 60 (OH) 9 O 7 Na 6 ; C 60 (OH) 11 O 8 Na 5 ; C 60 (OH) 11 O 12 Na 8 ; C 60 (OH) 11 O 20 Na 10 K 6 ; C 60 (OH) 6 O 4 Na 4 ; C 60 (OH) 20 O 8 Na 4 ; C 60 (OH) 10 O 13 Na 6 ; C 60 (OH) 4 O 14 Na 17 ; C 60 (OH) 13 O 4 Na 3 ; C 60 (OH) 10 ; C 60 (OH) 22-24 ; C 60 (OH) 36 ; C 60 (OH) 44 ; C 60 O 13 Na 14 ; Gd@C 82 (OH) 15 O 12 Na 5 ; Gd 3 N@C 80 (OH) 13 O 9 Na 6 ; C 60 (OH) 11 O 8 S 8 Na 5 ; C 60 (OH) 11 (SH) 5 O 8 Na 5 ; C 60 C 12 N 4 H 24
- the fullerenes in food product are two or more types of fullerenes selected from the group consisting of: C 60 (OH) 9 O 7 Na 6 ; C 60 (OH) 11 O 8 Na 5 ; C 60 (OH) 11 O 12 Na 8 ; C 60 (OH) 11 O 20 Na 10 K 6 ; C 60 (OH) 6 O 4 Na 4 ; C 60 (OH) 20 O 8 Na 4 ; C 60 (OH) 10 O 13 Na 6 ; C 60 (OH) 4 O 14 Na 17 ; C 60 (OH) 13 O 4 Na 3 ; C 60 (OH) 10 ; C 60 (OH) 22-24 ; C 60 (OH) 36 ; C 60 (OH) 44 ; C 60 O 13 Na 14 ; Gd@C 82 (OH) 15 O 12 Na 5 ; Gd 3 N@C 80 (OH) 13 O 9 Na 6 ; C 60 (OH) 11 O 8 S 8 Na 5 ; C 60 (OH) 11 (SH) 5 O 8 Na 5 ; C 60 C 12 N 4 H 24
- FIG. 1 Polyhydroxy fullerenes (PHF) catalytically produces hydrogen sulfide (H2S).
- Panel A Different PHF formulations MER, SJJR, and JR stimulate H2S production catalytically in a cell free chemical reaction involving cysteine and vitamin B6 as determined by the lead acetate/lead sulfide method (left image) and quantified in the graph to the right. * indicates significant difference (p ⁇ 0.05) compared to reaction (R ⁇ n) mix control using Student's T-test.
- Panel B PHF dose—dependently boosts endogenous H2S production in human liver derived (HepG2) cells as determined by an increase in the fluorescence of an H2S detecting chemical probe. * indicates significant difference (p ⁇ 0.05) compared to 0 PHF control group using Student's T-test.
- FIG. 2 Catalytic production of H2S: PHF (SJJR; 10 mg/mL) was added to a mixture of L-cysteine (10 mM) and pyridoxal L-phosphate (PLP; 1 mM) in a 96-well plate and then covered with a blotting paper saturated with lead acetate. After 24 hours, the lead acetate paper was removed and scanned. The lead sulfide dots were analyzed for average integrated density using ImageJ. After every 24 hours, the wells were replenished with L-cysteine (10 mM) and covered with the lead acetate paper and the lead sulfide dots were analyzed. The figure shows that the H2S production does not decrease with time showing that PHF is not consumed and hence, PHF is a catalyst.
- FIG. 3 Panel A) a hypothetical schematic illustration of the breakdown of cysteine to hydrogen sulfide, ammonia and pyruvic acid. While the present disclosure is not limited to any particular mechanism and an understanding of the mechanism is not necessary to practice the invention, it is believed that polyhydroxy fullerenes (PHF) mimic carbon-sulfur lyases. It was found during work conducted during development of embodiments herein that PHFs catalyze the breakdown of cysteine under physiological conditions.
- Panel C HR-TEM image of CGL showing a molecular size of 4.1 ⁇ 0.4 nm.
- FIGS. 4A-D Catalytic properties of PHF.
- FIG. 4A Effect of PHF concentration on H2S production from cysteine (initial concentration of 40 mM) in the presence or absence of pyridoxal-5′-phosphate (PLP).
- FIG. 4B Confirmation of PHF's role as a catalyst. Every 24 hours, 10 mM of cysteine was added, whereas PHF was not replenished. The absence of decline in H2S production indicates that PHF is a catalyst and not a reactant. No further additions of cysteine were made after day 17.
- FIG. 4C and FIG.
- FIG. 5 Steady-state kinetics of H2S production. Michaelis-Menten kinetics for PHF-catalyzed H2S production with: Panel A) cysteine, Panel B) homocysteine and Panel C) n-acetyl cysteine as substrates. No H2S production was observed with methionine as substrate. PLP (when added) initial concentration was 1 mM; PHF concentration was 10 mg/mL.
- FIG. 6 Effect of PHF structure on H2S production kinetics with cysteine as substrate.
- Michaelis-Menten kinetics for H2S production in presence of PLP with different molecular structures of PHF A) C 60 (OH) 9 O 7 Na 6 , B) C 60 (OH) 11 O 8 Na 5 , C) C 60 (OH) 11 O 12 Na 8 and D) C 60 (OH) 11 O 20 Na 10 K 6 .
- PLP initial concentration was 1 mM; PHF concentration was 10 mg/mL.
- FIG. 7 Application of PHF to rescue CGL deficiency.
- A) Kaplan-Meir survival curve for female CGL knockout mice on high-fat diet and i.p. injections of saline or PHF (200 ⁇ L) three times a week. The median survivals for control and PHF were 11 and 39 days, respectively. The P value from Log-rank (Mantel-Cox) test was 0.0061. (n 6).
- FIG. 8 Application of PHF to treat metabolic disease.
- Panel A) The food consumption in saline and PHF treated mice is similar over 8 weeks.
- Panel B) The saline treated mice have gained more body weight than PHF-treated mice even with similar food consumption.
- Panel C) The glucose tolerance of PHF-treated mice is higher, whereas saline-treated mice show symptoms of diabetes.
- FIG. 9 PHF catalytically cleaves C—SH bond in a peptide. Effect of PHF concentration on H2S production from glutathione (initial concentration of 10 mM) in the presence or absence of pyridoxal-5′-phosphate (PLP). Glutathione is a 3 amino acid peptide with cysteine in center. PLP does not enhance PHF's catalytic activity.
- medical food is as defined by the Orphan Drug Act (21 U.S.C. 360ee(b)(3)) of 1988, which is “a food which is formulated to be consumed or administered enterally under the supervision of a physician and which is intended for the specific dietary management of a disease or condition for which distinctive nutritional requirements, based on recognized scientific principles, are established by medical evaluation.”
- the terms “subject” and “patient” refer to any animal, such as a mammal like a dog, cat, bird, livestock, and preferably a human (e.g., a human with a disease such as asthma, a fibrotic disease, obesity, etc.).
- the term “administration” refers to the act of giving a drug, prodrug, or other agent (e.g., food product), or therapeutic treatment to a subject.
- exemplary routes of administration to the human body can be through the mouth (oral), skin (transdermal, topical), nose (nasal), lungs (inhalant), oral mucosa (buccal), by injection (e.g., intravenously, subcutaneously, intratumorally, intraocular, intraperitoneally, etc.), and the like.
- fullerene refers a general class of molecules that exists essentially in the shape of a three dimensional polyhedron containing from 20 to 1500 carbon atoms, and which comprises carbon atoms as the predominant element from which they are composed.
- the fullerenes include but are not limited to C-28, C-32, C-44, C-50, C-58, C-60, C-70, C-84, C-94, C-250 and C-540. According to this nomenclature, the fullerene which contains 60 carbon atoms is denoted C-60, the fullerene which contains 70 carbon atoms is denoted C-70, etc. Also included among the fullerenes are the substituted fullerenes.
- molecular fullerenes which have had one or more of the atoms which comprise the fullerene cage structure replaced by an atom other than carbon, such as nitrogen, boron or titanium, yet essentially retain the geometry of a polyhedron upon being so substituted.
- an atom other than carbon such as nitrogen, boron or titanium
- endohedral fullerenes in which atoms of elements other than carbon (e.g., iron, gadolinium and sulfur) reside inside the cage structure.
- fullerene is a “functionalized fullerene” which refers to fullerene (C x where x is 20 to 1500) with side groups attached to the outer surface of the cage via covalent bonds, ionic bonds, or Dewar coordination, or Kubas interactions, or any combination thereof.
- the side groups can be either inorganic, including, but not exclusive to, OH, Br, H 2 , Gd, Ti, organic, including, but not exclusive to, C(COOH) 2 , or any combination of organic and/or inorganic functional groups.
- the number of functional groups attached per cage of fullerene can vary from 1 to a majority of the number of carbons in the fullerene cage.
- the fullerenes herein are compounds according to the formula C 2n (OH) t (SH) u (NH 2 ) v (COOH) w (COOM) x O y M z , wherein M is an alkali metal, alkaline earth metal, transition metal, post-transition metal, lanthanide or actinide, n is a number ranging from 10 to 270; t, u, v, w, x, y and z can range from 0 to the total number of carbon atoms present in the cage. Examples of fullerenes are found in U.S. Pat. No. 9,950,977, which is herein incorporated by reference, in its entirety, particularly for the fullerene compounds disclosed therein.
- the fullerenes employed herein are polyhydroxy fullerenes (PHFs).
- compositions, systems, kits, and methods for treating a subject with a disease or condition by administering a composition comprising fullerenes to the subject such that H2S is generated in said subject.
- the disease or condition is associated with inflammation and/or below normal H2S levels.
- the fullerenes are polyhydroxy fullerenes (PHFs).
- H2S polyhydroxy fullerenes
- the catalytic activity of PHF and the endogenous H2S production rate is controlled by incorporating PHF in various matrices, such as inorganic, polymeric or metallic. Further, varying the size of the PHF-containing particles and distribution of PHF in matrices affect the catalytic activity and endogenous production rate.
- PHF catalytically generates H2S with amino acids (cysteine and homocysteine), and enhances endogenous production of H2S in liver cells.
- the fullerenes employed herein e.g., PHFs
- Table 1 below provides a comparison of steady state kinetic coefficients for PHF and CGL, with different substrates in presence and absence of PLP.
- Hydrogen sulfide is a gaseous transmitter in the blood that acts as a potent anti-oxidant, has anti-inflammatory activity and stimulates NO, thus a target for improving vascular health.
- H2S activity In vitro data has shown the H2S activity and previous animal studies with the fullerene have shown benefits in aging.
- sulfur-containing compound that serves as the substrate for fullerenes includes, for example, different sulfur-containing amino acids including cysteine, homocysteine, methionine and N-acetyl cysteine.
- PLP Viamin B6, which is a co-factor for enzymatic production of H 2 S
- the fullerenes described herein are employed with carriers (e.g., particles or devices).
- particle matrix carriers include, for example, Polymers: PLGA, PLA, PCL, PEG, Chitosan, alginate, pluronics, lipids and Eudragit;
- Inorganic Silica, silicon, titanium dioxide, ceria and amorphous carbon;
- Metals Gold, silver and copper; and Eudragit polymers that are either time-dependent release or pH-sensitive and may be preferable for medical food, whereas silica may be preferable for topical application and PEG coated particles for intravenous administration.
- the fullerenes described herein may be used to treat a subject in order to treat a disease or condition.
- the type of administration is not limited, and could be intravenous, intraocular, topical, etc.
- the disease or condition is, for example, heart failure (HF), heart disease (HD), chronic kidney disease, Alzheimer's disease (AD) and peripheral artery disease (PAD).
- HF heart failure
- HD heart disease
- AD Alzheimer's disease
- PAD peripheral artery disease
- cardiovascular disease e.g., heart failure or chronic heart failure
- cardiovascular disease e.g., heart failure or chronic heart failure
- heart failure it has been shown that hydrogen sulfide is inversely correlated to severity of disease and to poor prognosis.
- Cardiovascular is a brood classification of a disease area that has many different manifestations, including hypertension, dyslipdemia, chronic heart failure, stroke, acute heart failure, angina, atrial fibrillation and peripheral arterial disease.
- the total cardiovascular market was estimated at ⁇ $145 billion in 2007, with the majority of the market being attributed to hypertension and dyslipidemia. While these segments have been well served, others such as chronic and acute heart failure remain largely symptomatically treated.
- the American Heart Association estimates the prevalence of heart failure in the U.S. is estimated near 6 million and analyst expected it to grow to 9 million by 2022. While the disease does occur in all ages, it is predominantly a disease of the elderly and a driver of the expansion due to the aging population.
- Heart failure the most common cause of hospitalization in the US and total treatment costs continue to rise each year. Heart failure is estimated to account for over $40 billion in total costs and results in almost 1 ⁇ 2 million deaths annually in the US alone.
- Chronic heart failure is a condition in which the heart can not pump blood adequately and can arise from genetic defect, injury or disease.
- the inability to deliver blood efficiently to the body leads to shortness of breath, tiredness, and edema (build up of fluids), which further exasperates the shortness of breath and tiredness.
- the cardiac structural and functional dysfunction that is characterized in heart failure is often defined in terms of the left ventricle ejection fraction (LVEF).
- EF left ventricle ejection fraction
- EF left ventricle ejection fraction
- EF left ventricle ejection fraction
- HF-REF reduced EF
- HF-PEF preserved EF
- Normal EF is usually considered to be above 50%.
- Patients with reduced EF the left ventricle (LV) is unable to contract properly and ejects smaller fraction of blood than normal.
- Patients with preserved EF have normal LVEF but have LV diastolic dysfunction.
- patients with preserved EF have an increase in LV wall thickness and increased left at
- the drugs available for treating chronic heart failure are largely enzyme inhibitors or receptor agonists or antagonists which may improve outcome but do not treat the underlying disease.
- hydrogen sulfide prodrugs have been shown in animal studies to improve ventricular function, including ejection fraction and actually reverse disease progression.
- fullerenes are used to generate H2S in vivo to treat alcoholism, opioid withdrawal, or heroin withdrawal. In certain embodiments, fullerene are used to generate H2S in vivo to treat Alzheimer's disease or chronic fatigue syndrome. In certain embodiments, fullerenes are used to generate H2S in vivo to improve social interaction or treat abnormal behavior. In certain embodiments, fullerenes are used to generate H2S in vivo to treat ulcers, airway inflammation, diabetes, obesity, and for causing weight loss.
- fullerenes are used to generate H2S in vivo to treat epilepsy, erectile dysfunction (ED), depression, anxiety, Huntington's disease, high blood pressure, hypertension, colitis, sleep apnea, and Parkinson's disease (PD).
- fullerenes are used to generate H2S in vivo to reduce the severity of neurological injury or prevent stroke.
- fullerenes are used to generate H2S in vivo to treat pulmonary hypertension or prevent renal fibrosis.
- fullerenes are used to generate H2S in vivo to treat gout, a rheumatic disease, skin conditions (including skin disease or cosmetic condition), ocular diseases and osteoarthritis.
- fullerenes are used to treat conditions such as hyperhomocysteinemia, homocystinuria, cystinuria, and cystine stones.
- the fullerenes described herein is applied locally, such as to the skin, eye, or joint of a subject.
- a local application such as a dermal application
- the application is performed at a defined part of the skin (e.g. to a skin area, wherein the skin condition occurs or is expected to occur).
- the local application may include treating a skin area superficially, intradermally or subcutaneously, i.e. by injection under the skin area of issue.
- a local application to the ocular tissues may be employed.
- the local application may include applying the compound for use according to the invention on the ocular surface, e.g.
- the compound for use according to the invention may be administered as vitreous body substitute or as intraocular implant.
- the fullerenes described herein are used to treat osteoarthritis with a local application to a joint.
- the compound for use according to the invention may be administered as viscosupplement.
- a viscosupplement is injected as a gel into the joint of issue, e.g. knee, referred to as intraarticular injection.
- the fullerene compositions according to the present technology comprises or consists of a pharmaceutically acceptable carrier, diluent, or excipient (including combinations thereof).
- Acceptable carriers or diluents for therapeutic use are well known in the pharmaceutical art and are described, for example, in Remington's Pharmaceutical Sciences, Mack Publishing Co. (A. R. Gennaro edit. 1985).
- the choice of pharmaceutical carrier, excipient, or diluent is selected with regard to the intended route of administration and standard pharmaceutical practice.
- the pharmaceutical comprise as, or in addition to, the carrier, excipient, or diluent any suitable binder(s), lubricant(s), suspending agent(s), coating agent(s), and/or solubilizing agent(s).
- This pharmaceutical composition will desirably be provided in a sterile form. It may be provided in unit dosage form and will generally be provided in a sealed container. A plurality of unit dosage forms may be provided.
- compositions within the scope of the present technology may include one or more of the following: preserving agents, solubilizing agents, stabilizing agents, wetting agents, emulsifiers, sweeteners, colorants, flavoring agents, odorants, and/or salts.
- Compounds of the present technology may themselves be provided in the form of a pharmaceutically acceptable salt.
- embodiments may comprise buffers, coating agents, antioxidants, suspending agents, adjuvants, excipients, and/or diluents. Examples of preservatives include sodium benzoate, sorbic acid, and esters of p-hydroxybenzoic acid.
- compositions of the present technology may also contain other therapeutically active agents in addition to compounds of the present technology. Where two or more therapeutic agents are used they may be administered separately (e.g., at different times and/or via different routes) and therefore do not always need to be present in a single composition. Thus, combination therapy is within the scope of the present technology.
- the routes for administration include, but are not limited to, one or more of: oral (e.g. as a tablet, capsule, or as an ingestable solution), topical, mucosal (e.g. as a nasal spray or aerosol for inhalation), nasal, parenteral (e.g. by an injectable form), gastrointestinal, intraspinal, intraperitoneal, intramuscular, intravenous, intrauterine, intraocular, intradermal, intracranial, intratracheal, intravaginal, intracerebroventricular, intracerebral, subcutaneous, ophthalmic (including intravitreal or intracameral), transdermal, rectal, buccal, via the penis, vaginal, epidural, sublingual. It is to be understood that not all of the agent need be administered by the same route. Likewise, if the composition comprises more than one active component, then those components may be administered by different routes.
- fullerenes described herein is administered parenterally
- examples of such administration include one or more of: intravenously, intra-arterially, intraperitoneally, intrathecally, intraventricularly, intraurethrally, intrastemally, intracranially, intramuscularly, or subcutaneously administering the agent; and/or by using infusion techniques.
- compositions adapted for oral administration are provided as capsules or tablets; as powders or granules; as solutions, food product, syrups or suspensions (in aqueous or non-aqueous liquids); as edible foams or whips; or as emulsions.
- Tablets or hard gelatin capsules may comprise lactose, maize starch or derivatives thereof, stearic acid or salts thereof.
- Soft gelatin capsules may comprise vegetable oils, waxes, fats, semi-solid, or liquid polyols etc.
- Solutions and syrups may comprise water, polyols and sugars.
- oils e.g., vegetable oils
- An active agent intended for oral administration may be coated with or admixed with a material that delays disintegration and/or absorption of the active agent in the gastrointestinal tract (e.g., glyceryl monostearate or glyceryl distearate may be used).
- a material that delays disintegration and/or absorption of the active agent in the gastrointestinal tract e.g., glyceryl monostearate or glyceryl distearate may be used.
- a material that delays disintegration and/or absorption of the active agent in the gastrointestinal tract e.g., glyceryl monostearate or glyceryl distearate may be used.
- glyceryl monostearate or glyceryl distearate may be used.
- the fullerenes described herein may be applied topically in the form of a gel, hydrogel, lotion, solution, cream, ointment or dusting powder.
- the agent of the present technology may also be dermally or transdermally administered, for example, by the use of a skin patch.
- the agent of the present technology can be formulated as a suitable ointment containing the active compound suspended or dissolved in, for example, a mixture with one or more of the following: mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene polyoxypropylene compound, emulsifying wax and water.
- a suitable lotion or cream suspended or dissolved in, for example, a mixture of one or more of the following: mineral oil, sorbitan monostearate, a polyethylene glycol, liquid paraffin, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.
- mineral oil sorbitan monostearate
- a polyethylene glycol liquid paraffin
- polysorbate 60 cetyl esters wax
- cetearyl alcohol cetearyl alcohol
- 2-octyldodecanol benzyl alcohol and water.
- examples of such administration include one or more of intravenously, intra-arterially, intraperitoneally, intrathecally, intraventricularly, intraurethrally, intrasternally, intracranially, intramuscularly or subcutaneously administering the agent; and/or by using infusion techniques.
- the actual dosage of the fullerenes which will be most suitable for an individual subject.
- the specific dose level and frequency of dosage for any particular patient may be varied and will depend upon a variety of factors including the activity of the specific compound employed; the metabolic stability and length of action of that compound; the age, body weight, general health, sex, diet, mode and time of administration; rate of excretion; drug combination; the severity of the particular condition; and the individual undergoing therapy.
- the agent and/or the pharmaceutical composition of the present technology may be administered in accordance with a regimen of from 1 to 10 times per day, such as once or twice per day.
- the daily dosage level of the agent may be in single or divided doses.
- “Therapeutically effective amount” refers to the amount of the fullerenes describe herein that is effective to achieve its intended purpose (e.g., treating symptoms of an inflammatory disease or other disease or condition described herein). The methods described herein may employ a daily therapeutically effective amount. While individual patient needs may vary, determination of optimal ranges for effective amounts of the compounds related to the technology is within the skill of the art.
- the dosage regimen for treating a condition with the compounds and/or compositions of this technology is selected in accordance with a variety of factors, including the type, age, weight, sex, diet and medical condition of the patient; the severity of the dysfunction; the route of administration; pharmacological considerations such as the activity, efficacy, pharmacokinetic and toxicology profiles of the particular compound used; whether a drug delivery system is used; and whether the compound is administered as part of a drug combination and can be adjusted by one skilled in the art.
- the dosage regimen actually employed may vary widely and therefore may deviate from the exemplary dosage regimens set forth herein.
- the particular molecular structure of a given PHF is varied depending on the type of substrate, temperature, ionic strength, pH and the desired catalysis rate. For example, in general, if higher substrate affinity is desired, then the number of ionic functional groups (e.g., (OH), O or NH) is increased, and if higher catalytic rate is desired, then the number of functional groups is decreased. Further, in work conducted during the development of embodiments herein, it was observed that addition of thiol groups or disulfide groups can significantly increase catalytic activity.
- ionic functional groups e.g., (OH), O or NH
- H2S is produced from cysteine by the enzymes cystathionine ⁇ -synthase (CBS) and cystathionine ⁇ -lyase (CGL) in the body. It was discovered that: 1) PHF catalytically produces H2S from cysteine and homocysteine ( FIG. 1A ), and 2) PHF enhances endogenous production of H2S ( FIG. 1B ). Further, the catalytic activity depends on the molecular structure of PHF ( FIG. 1A ). FIG. 1 shows that polyhydroxy fullerenes (PHF) catalytically produces hydrogen sulfide (H2S).
- PHF polyhydroxy fullerenes
- FIG. 1A shows that polyhydroxy fullerenes (PHF) catalytically produces hydrogen sulfide (H2S) with different PHF formulations MER, SJJR, and JR stimulate H2S production catalytically in a cell free chemical reaction involving cysteine and vitamin B6 as determined by the lead acetate/lead sulfide method (left image) and quantified in the graph to the right.
- * indicates significant difference (p ⁇ 0.05) compared to reaction (R ⁇ n) mix alone
- FIG. 1B shows PHF dose—dependently boosts endogenous H2S production in human liver derived (HepG2) cells as determined by an increase in the fluorescence of an H2S detecting chemical probe.
- MER C 60 (OH) 11 O 8 Na 7 (note that the manufacturer says that their PHF is C 60 (OH) 24 and our characterization shows it different); ii) SJJR: C 60 (OH) 10 O 6 Na 4 ; and iii) JR: C 60 (OH) 23 O 5 Na 4 .
- FIG. 2 shows that the H2S production does not decrease with time showing that PHF is not consumed and hence, PHF is a catalyst.
- PHFs with general formula of a) C60(OH)tOyMzM′z′ and b) C60(OH)t(SH)uOyMz or C60(OH)t(S)uOyMz, were employed.
- Examples of a) include: C 60 (OH) 9 O 7 Na 6 ; C 60 (OH) 11 O 8 Na 5 ; C 60 (OH) 11 O 12 Na 8 ; and C 60 (OH) 11 O 20 Na 10 K 6 ;
- the kinetics and catalysis coefficients for PHF catalyzed H 2 S production were determined using lead acetate assay (PbA/PbS assay) as generally described in Hine and Mitchell, “Endpoint and Kinetic Measurement of Hydrogen Sulfide Production Capacity in Tissue Extracts” Bio-Protocol, 7 (13), e2382, 2017). Briefly: Reaction mixtures (150 ⁇ L/well) containing PHF or enzyme (CGL), enzyme co-factor (PLP) and substrate (e.g., cysteine) were tested in 96-well plates. Immediately after addition of catalyst, 96-well plates were covered with lead acetate saturated paper and placed inside a 37° C. cell culture incubator.
- PbA/PbS assay lead acetate assay
- the lead acetate paper was removed and scanned, and the lead sulfide dots analyzed with ImageJ using the IntDen function.
- a calibration curve was prepared with different concentrations of sodium hydrosulfide plotted against the integrated density obtained on lead acetate/lead sulfide paper. The presence of pyruvic acid after reaction was confirmed in a preliminary experiment by liquid chromatography-mass spectroscopy.
- Cysteine by itself under physiological conditions, does not breakdown to produce H 2 S ( FIG. 4 a ).
- PLP reacts with cysteine slowly to produce H 2 S (0.024 mM in 24 hours).
- Addition of PHF to the cysteine-PLP mixture increased H 2 S production in a concentration dependent manner.
- H 2 S production with PHF was observed even in the absence of PLP.
- H 2 S production increased with addition of PLP at every concentration of PHF tested. Since H 2 S generation in both the presence and absence of PLP was highest at 10 mg/mL PHF, further experiments were carried out at this concentration.
- FIG. 4 b shows that PHF is a catalyst as the amount of H 2 S produced does not decrease with repeated addition of substrate in presence or absence of PLP.
- the catalytic activity of PHF is dependent on pH and temperature. Experiments at different pH were carried out in deionized water instead of PBS ( FIG. 4 c ). PHF catalytically produced H 2 S at all pH tested with maximum production around pH 7. Addition of PLP enhanced the amount of H 2 S produced without affecting the trend with pH.
- Polyhydroxy fullerenes can be synthesized with different number of hydroxyl and hemi-ketal groups attached to fullerene cage, which can be determined with XPS C1s spectrum as mono-oxygenated and di-oxygenated carbon, respectively.
- Different PHF structures were synthesized and their K M and V Max were determined ( FIGS. 6 a - d ). The higher the total number of functional groups greater is the production of H 2 S. Further, with increase in functional groups K M and V Max decreases ( FIG. 4 e ).
- the K M value for PHF with highest number of functional group tested (31) was similar to CGL enzyme, however, the V Max for PHF31 was 10 fold higher than CGL enzyme.
- mice were fed with high-fat/high salt (HFHS) diet.
- HFHS high-fat/high salt
- the HFHS diet is expected to induce obesity in mice and reduce their glucose tolerance.
- 100 g of HFHS food was added to each cage. Every week, the amount remaining was measured and replenished to a total weight of 100 g.
- FIG. 8 a shows that there was no difference in the amount of food consumed by PHF-treated or control mice over 8 weeks of experiments.
- the percent change in body weight for PHF-treated mice was lower than control mice ( FIG. 8B ).
- glucose tolerance test suggested that PHF-treated mice have normal glucose tolerance compared to control mice that exhibit diabetic symptoms ( FIG. 8C ).
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Materials Engineering (AREA)
- Nanotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Provided herein are compositions, systems, kits, and methods for treating a subject with a disease or condition by administering a composition comprising fullerenes to the subject such that H2S is generated in said subject. In certain embodiments, the disease or condition is associated with inflammation and/or below normal H2S levels. In certain embodiments, the fullerenes are polyhydroxy fullerenes (PHFs).
Description
- The present application claims priority to U.S. Provisional application Ser. No. 62/735,621, filed Sep. 24, 2018, herein incorporated by reference in its entirety.
- Provided herein are compositions, systems, kits, and methods for treating a subject with a disease or condition by administering a composition comprising fullerenes to the subject such that H2S is generated in said subject. In certain embodiments, the disease or condition is associated with inflammation and/or below normal H2S levels. In certain embodiments, the fullerenes are polyhydroxy fullerenes (PHFs).
- Within the past decade, it has become apparent that hydrogen sulfide (H2S) gas plays a strong role in aging and health (Hine et al., 2017; Zhang et al., 2013). H2S is a signaling molecule with multitude of biological functions and is produced from cysteine by the enzymes cystathionine β-synthase (CBS) and cystathionine γ-lyase (CGL). Reduction in production levels of endogenous H2S has been implicated in many diseases including aging (Huang et al., 2015; Yang et al., 2008), cardiovascular (Kovacic et al., 2012), metabolic (Szabo, 2012) (Liu et al., 2014) and neurodegenerative disorders (Paul et al., 2014). Exposure to supra-physiological levels of H2S can be beneficial. For example, in rodents H2S increases vasodilation of blood vessels and lowers blood pressure (Zhao et al., 2001), protects against ischemia reperfusion injury to multiple organs including heart (Elrod et al., 2007) and liver (Jha et al., 2008), improves insulin sensitivity and/or responses to glucose (Suzuki et al., 2011; Xue et al., 2013), delays cognitive decline in animal models of Alzheimer's disease (Giuliani et al., 2013), and is associated or causative of extended longevity (Hine et al., 2015).
- Exogenous H2S supplementation is conceptually the most straightforward, with multiple different forms of H2S already available, from the short-acting gas itself (Blackstone et al., 2005) to short- and long-lasting chemical H2S donors (Alves et al., 2011; Polhemus et al., 2015). However, due to the gas and donors being highly reactive, this approach risks acute toxicity, so that targeted delivery to the proper organ and cell type at the optimal dose may be challenging to achieve. Two of the most potent mechanisms to boost endogenous enzymatic H2S production for beneficial endpoints is via dietary restriction (Hine et al., 2015) and lowering of growth hormone and thyroid hormone signaling via dietary, pharmacological, or genetic means (Hine et al., 2017). However, the translatability of these two interventions to boost H2S in humans is poor, as patient compliance and safety issues prevent them from being widely implemented. Additionally, mutations or epigenetic gene-silencing present in the human population for CBS (Sponholz et al., 2016) or CGL (Zhu et al., 2008) that result in impaired enzymatic activity would negate these types of interventions.
- Provided herein are compositions, systems, kits, and methods for treating a subject with a disease or condition by administering a composition comprising fullerenes to the subject such that H2S is generated in said subject. In certain embodiments, the disease or condition is associated with inflammation and/or below normal H2S levels. In certain embodiments, the fullerenes are polyhydroxy fullerenes (PHFs).
- In some embodiments, provided herein are methods of treating a subject with a disease or condition comprising: administering a composition comprising fullerenes to said subject with said disease or condition (e.g., such that H2S is generated in said subject). In certain embodiments, the disease or condition is associated with inflammation and/or below normal H2S levels in said subject. In further embodiments, the administering reduces or eliminates at least one symptom of said disease or condition.
- In some embodiments, the fullerenes comprise polyhydroxy fullerenes. In certain embodiments, the fullerenes in said composition are all one type of fullerene. In further embodiments, the fullerenes in the composition are two or more types of fullerenes. In other embodiments, the fullerenes in the composition are all one type of fullerene selected from the group consisting of: C60(OH)9O7Na6; C60(OH)11O8Na5; C60(OH)11O12Na8; C60(OH)11O20Na10K6; C60(OH)6O4Na4; C60(OH)20O8Na4; C60(OH)10O13Na6; C60(OH)4O14Na17; C60(OH)13O4Na3; C60(OH)10; C60(OH)22-24; C60(OH)36; C60(OH)44; C60O13Na14; Gd@C82(OH)15O12Na5; Gd3N@C80(OH)13O9Na6; C60(OH)11O8S8Na5; C60(OH)11(SH)5O8Na5; C60C12N4H24; and C60C12N6H30O12. In other embodiments, the fullerenes in said composition are two or more types of fullerenes selected from the group consisting of: C60(OH)9O7Na6; C60(OH)11O8Na5; C60(OH)11O12Na8; C60(OH)11O20Na10K6; C60(OH)6O4Na4; C60(OH)20O8Na4; C60(OH)10O13Na6; C60(OH)4O14Na17; C60(OH)13O4Na3; C60(OH)10; C60(OH)22-24; C60(OH)36; C60(OH)44; C60O13Na14; Gd@C82(OH)15O12Na5; Gd3N@C80(OH)13O9Na6; C60(OH)11O8S8Na5; C60(OH)11(SH)5O8Na5; C60C12N4H24; and C60C12N6H30O12. In certain embodiments, the fullerenes are one or more compounds according to the formula C2n(OH)t(SH)u(NH2)v(COOH)w(COOM)xOyMz, wherein M is an alkali metal, alkaline earth metal, transition metal, post-transition metal, lanthanide or actinide, n is a number ranging from 10 to 270; and t, u, v, w, x, y and z can range from 0 to the total number of carbon atoms present in the cage.
- In particular embodiments, the composition comprises a food product. In certain embodiments, the food product comprises carbohydrates, proteins, and fats. In other embodiments, the food product is in a form selected from the group consisting of: mayonnaise, margarine, low fat spread, yoghurt, a fruit smoothie, a beverage, a protein smoothie, a cheese spread, processed cheese, a dairy dessert, a flavored milk, cream, a fermented milk product, cheese, butter, a condensed milk product, an ice cream mix, a soy product, pasteurized liquid egg, a bakery product, a confectionary product, confectionary bar, chocolate bar, high fat bar, energy bar, liquid emulsion, powder, spray dried powder, freeze dried powder, pudding, a gel, a gel concentrate, a liquid drink, and jelly. In certain embodiments, said composition is located in a skin patch or eye drop solution.
- In some embodiments, provided herein are methods of comprising: contacting a sulfur-containing compound or thiol-containing compound, with a composition comprising fullerenes in vitro such that H2S is generated. In certain embodiments, the methods further comprise capturing at least some of said H2S that is generated. In additional embodiments, the capture H2S is stored. In certain embodiments, the fullerenes are used in various biotechnology methods for processing amino acids.
- In some embodiments, provided herein are compositions or articles of manufacture comprising: a food product, wherein said food product comprises a composition comprising fullerenes. In additional embodiments, the food product comprises carbohydrates, proteins, and fats. In further embodiments, the food product is in a form selected from the group consisting of: mayonnaise, margarine, low fat spread, yoghurt, a fruit smoothie, a protein smoothie, a cheese spread, processed cheese, a dairy dessert, a flavored milk, cream, a fermented milk product, cheese, butter, a condensed milk product, an ice cream mix, a soy product, pasteurized liquid egg, a bakery product, a confectionary product, confectionary bar, chocolate bar, high fat bar, energy bar, liquid emulsion, powder, spray dried powder, freeze dried powder, pudding, a gel, a gel concentrate, a liquid drink, and jelly. In certain embodiments, the food product qualifies as a medical food as defined in the Orphan Drug Act.
- In certain embodiments, the fullerenes in the food product comprise polyhydroxy fullerenes. In additional embodiments, the fullerenes in said food product are all one type of fullerene. In other embodiments, the fullerenes in the food production are two or more types of fullerenes. In some embodiments, the fullerenes in the food product are all one type of fullerene selected from the group consisting of: C60(OH)9O7Na6; C60(OH)11O8Na5; C60(OH)11O12Na8; C60(OH)11O20Na10K6; C60(OH)6O4Na4; C60(OH)20O8Na4; C60(OH)10O13Na6; C60(OH)4O14Na17; C60(OH)13O4Na3; C60(OH)10; C60(OH)22-24; C60(OH)36; C60(OH)44; C60O13Na14; Gd@C82(OH)15O12Na5; Gd3N@C80(OH)13O9Na6; C60(OH)11O8S8Na5; C60(OH)11(SH)5O8Na5; C60C12N4H24; and C60C12N6H30O12. In other embodiments, the fullerenes in food product are two or more types of fullerenes selected from the group consisting of: C60(OH)9O7Na6; C60(OH)11O8Na5; C60(OH)11O12Na8; C60(OH)11O20Na10K6; C60(OH)6O4Na4; C60(OH)20O8Na4; C60(OH)10O13Na6; C60(OH)4O14Na17; C60(OH)13O4Na3; C60(OH)10; C60(OH)22-24; C60(OH)36; C60(OH)44; C60O13Na14; Gd@C82(OH)15O12Na5; Gd3N@C80(OH)13O9Na6; C60(OH)11O8S8Na5; C60(OH)11(SH)5O8Na5; C60C12N4H24; and C60C12N6H30O12.
-
FIG. 1 : Polyhydroxy fullerenes (PHF) catalytically produces hydrogen sulfide (H2S). Panel A) Different PHF formulations MER, SJJR, and JR stimulate H2S production catalytically in a cell free chemical reaction involving cysteine and vitamin B6 as determined by the lead acetate/lead sulfide method (left image) and quantified in the graph to the right. * indicates significant difference (p<0.05) compared to reaction (R×n) mix control using Student's T-test. Panel B) PHF dose—dependently boosts endogenous H2S production in human liver derived (HepG2) cells as determined by an increase in the fluorescence of an H2S detecting chemical probe. * indicates significant difference (p<0.05) compared to 0 PHF control group using Student's T-test. -
FIG. 2 . Catalytic production of H2S: PHF (SJJR; 10 mg/mL) was added to a mixture of L-cysteine (10 mM) and pyridoxal L-phosphate (PLP; 1 mM) in a 96-well plate and then covered with a blotting paper saturated with lead acetate. After 24 hours, the lead acetate paper was removed and scanned. The lead sulfide dots were analyzed for average integrated density using ImageJ. After every 24 hours, the wells were replenished with L-cysteine (10 mM) and covered with the lead acetate paper and the lead sulfide dots were analyzed. The figure shows that the H2S production does not decrease with time showing that PHF is not consumed and hence, PHF is a catalyst. -
FIG. 3 : Panel A) a hypothetical schematic illustration of the breakdown of cysteine to hydrogen sulfide, ammonia and pyruvic acid. While the present disclosure is not limited to any particular mechanism and an understanding of the mechanism is not necessary to practice the invention, it is believed that polyhydroxy fullerenes (PHF) mimic carbon-sulfur lyases. It was found during work conducted during development of embodiments herein that PHFs catalyze the breakdown of cysteine under physiological conditions. Panel B) HR-TEM image of PHF (C60(OH)9O7Na6) showing a cluster size of 3.4±0.5 nm. Panel C) HR-TEM image of CGL showing a molecular size of 4.1±0.4 nm. -
FIGS. 4A-D : Catalytic properties of PHF.FIG. 4A ) Effect of PHF concentration on H2S production from cysteine (initial concentration of 40 mM) in the presence or absence of pyridoxal-5′-phosphate (PLP).FIG. 4B ) Confirmation of PHF's role as a catalyst. Every 24 hours, 10 mM of cysteine was added, whereas PHF was not replenished. The absence of decline in H2S production indicates that PHF is a catalyst and not a reactant. No further additions of cysteine were made after day 17.FIG. 4C ) andFIG. 4D ) Effect of temperature (C) and pH (D) on catalytic production of H2S with PHF in presence and absence of PLP. PLP (when added) initial concentration was 1 mM; PHF concentration (except for panel A) was 10 mg/mL. -
FIG. 5 : Steady-state kinetics of H2S production. Michaelis-Menten kinetics for PHF-catalyzed H2S production with: Panel A) cysteine, Panel B) homocysteine and Panel C) n-acetyl cysteine as substrates. No H2S production was observed with methionine as substrate. PLP (when added) initial concentration was 1 mM; PHF concentration was 10 mg/mL. -
FIG. 6 : Effect of PHF structure on H2S production kinetics with cysteine as substrate. Michaelis-Menten kinetics for H2S production in presence of PLP with different molecular structures of PHF: A) C60(OH)9O7Na6, B) C60(OH)11O8Na5, C) C60(OH)11O12Na8 and D) C60(OH)11O20Na10K6. E) Correlation of Km and Vmax with number of PHF functional groups. PLP initial concentration was 1 mM; PHF concentration was 10 mg/mL. -
FIG. 7 : Application of PHF to rescue CGL deficiency. A) Kaplan-Meir survival curve for female CGL knockout mice on high-fat diet and i.p. injections of saline or PHF (200 μL) three times a week. The median survivals for control and PHF were 11 and 39 days, respectively. The P value from Log-rank (Mantel-Cox) test was 0.0061. (n=6). B) The color of feces in PHF treated mice were dark brown due to PHF color. -
FIG. 8 : Application of PHF to treat metabolic disease. Panel A) The food consumption in saline and PHF treated mice is similar over 8 weeks. Panel B) The saline treated mice have gained more body weight than PHF-treated mice even with similar food consumption. Panel C) The glucose tolerance of PHF-treated mice is higher, whereas saline-treated mice show symptoms of diabetes. Female wild-type mice were fed with high fat/high salt diet and injected with 100 μL of PHF (1 mg/mL) or saline three times a week for 8 weeks. (n=5). -
FIG. 9 : PHF catalytically cleaves C—SH bond in a peptide. Effect of PHF concentration on H2S production from glutathione (initial concentration of 10 mM) in the presence or absence of pyridoxal-5′-phosphate (PLP). Glutathione is a 3 amino acid peptide with cysteine in center. PLP does not enhance PHF's catalytic activity. - To facilitate an understanding of the present technology, a number of terms and phrases are defined below. Additional definitions are set forth throughout the detailed description.
- Throughout the specification and claims, the following terms take the meanings explicitly associated herein, unless the context clearly dictates otherwise. The phrase “in one embodiment” as used herein does not necessarily refer to the same embodiment, though it may. Furthermore, the phrase “in another embodiment” as used herein does not necessarily refer to a different embodiment, although it may. Thus, as described below, various embodiments of the technology may be readily combined, without departing from the scope or spirit of the technology.
- In addition, as used herein, the term “or” is an inclusive “or” operator and is equivalent to the term “and/or” unless the context clearly dictates otherwise. In addition, throughout the specification, the meaning of “a”, “an”, and “the” include plural references. The meaning of “in” includes “in” and “on.”
- The term “medical food,” as used herein, is as defined by the Orphan Drug Act (21 U.S.C. 360ee(b)(3)) of 1988, which is “a food which is formulated to be consumed or administered enterally under the supervision of a physician and which is intended for the specific dietary management of a disease or condition for which distinctive nutritional requirements, based on recognized scientific principles, are established by medical evaluation.”
- As used herein, the terms “subject” and “patient” refer to any animal, such as a mammal like a dog, cat, bird, livestock, and preferably a human (e.g., a human with a disease such as asthma, a fibrotic disease, obesity, etc.).
- As used herein, the term “administration” refers to the act of giving a drug, prodrug, or other agent (e.g., food product), or therapeutic treatment to a subject. Exemplary routes of administration to the human body can be through the mouth (oral), skin (transdermal, topical), nose (nasal), lungs (inhalant), oral mucosa (buccal), by injection (e.g., intravenously, subcutaneously, intratumorally, intraocular, intraperitoneally, etc.), and the like.
- As used herein, “fullerene” refers a general class of molecules that exists essentially in the shape of a three dimensional polyhedron containing from 20 to 1500 carbon atoms, and which comprises carbon atoms as the predominant element from which they are composed. The fullerenes include but are not limited to C-28, C-32, C-44, C-50, C-58, C-60, C-70, C-84, C-94, C-250 and C-540. According to this nomenclature, the fullerene which contains 60 carbon atoms is denoted C-60, the fullerene which contains 70 carbon atoms is denoted C-70, etc. Also included among the fullerenes are the substituted fullerenes. These are molecular fullerenes which have had one or more of the atoms which comprise the fullerene cage structure replaced by an atom other than carbon, such as nitrogen, boron or titanium, yet essentially retain the geometry of a polyhedron upon being so substituted. Also included among the fullerenes are endohedral fullerenes, in which atoms of elements other than carbon (e.g., iron, gadolinium and sulfur) reside inside the cage structure. Included in the term “fullerene” is a “functionalized fullerene” which refers to fullerene (Cx where x is 20 to 1500) with side groups attached to the outer surface of the cage via covalent bonds, ionic bonds, or Dewar coordination, or Kubas interactions, or any combination thereof. The side groups can be either inorganic, including, but not exclusive to, OH, Br, H2, Gd, Ti, organic, including, but not exclusive to, C(COOH)2, or any combination of organic and/or inorganic functional groups. The number of functional groups attached per cage of fullerene can vary from 1 to a majority of the number of carbons in the fullerene cage. Functionalized fullerenes have different physical and chemical properties based on the type and number of side groups. In certain embodiments, the fullerenes herein are compounds according to the formula C2n(OH)t(SH)u(NH2)v(COOH)w(COOM)xOyMz, wherein M is an alkali metal, alkaline earth metal, transition metal, post-transition metal, lanthanide or actinide, n is a number ranging from 10 to 270; t, u, v, w, x, y and z can range from 0 to the total number of carbon atoms present in the cage. Examples of fullerenes are found in U.S. Pat. No. 9,950,977, which is herein incorporated by reference, in its entirety, particularly for the fullerene compounds disclosed therein. In certain embodiments, the fullerenes employed herein are polyhydroxy fullerenes (PHFs).
- Provided herein are compositions, systems, kits, and methods for treating a subject with a disease or condition by administering a composition comprising fullerenes to the subject such that H2S is generated in said subject. In certain embodiments, the disease or condition is associated with inflammation and/or below normal H2S levels. In certain embodiments, the fullerenes are polyhydroxy fullerenes (PHFs).
- In work conducted during embodiments of the present disclosure, experiments suggest that PHF exposed to H2S is modified and becomes catalytically more active than just PHF. While the present disclosure is not limited to any particular mechanism, and an understanding of the mechanism is not necessary to practice the invention, it is believed that PHF has been modified with thiol groups. Such thiol-modified PHF's are contemplated as one type of fullerene to be used with the methods, compositions, kits, and systems described herein.
- In work conducted during development of embodiments disclosed herein, it was determined that a carbon-based nanomaterial, polyhydroxy fullerenes (PHF) catalytically generates H2S from sulfur containing amino acids (e.g., cysteine) and enhances endogenous production of H2S. Hydrogen sulfide (H2S) is a gaseous signaling molecule with multitude of biological functions. Reduced endogenous levels of H2S has been implicated in metabolic, cardiovascular, neurologic and immunologic diseases. In general, the H2S production depended on the concentration of PHF and type of sulfur-containing compound (e.g., amino acid). In certain embodiments, the catalytic activity of PHF and the endogenous H2S production rate is controlled by incorporating PHF in various matrices, such as inorganic, polymeric or metallic. Further, varying the size of the PHF-containing particles and distribution of PHF in matrices affect the catalytic activity and endogenous production rate. Work conducted during development of embodiments disclosed herein demonstrated that PHF catalytically generates H2S with amino acids (cysteine and homocysteine), and enhances endogenous production of H2S in liver cells. In certain embodiments, the fullerenes employed herein (e.g., PHFs) are pre-exposed to H2S gas or NaHS in liquid form. In this regard, such pre-exposed fullerenes may exhibit enhanced catalytic activity.
- Table 1 below provides a comparison of steady state kinetic coefficients for PHF and CGL, with different substrates in presence and absence of PLP.
-
TABLE 1 KCAT/ Km Vmax KCAT KM Catalyst Substrate (mM) (nM/s) (/s) (/Ms) With CGL L-Cysteine 25.4 2.9 1.3 × 102 0.507 PLP PHF L-Cysteine 26.4 9.1 6.7 × 104 0.023 PHF D,L- 62.3 1.7 1.3 × 104 0.002 Homocysteine PHF N-Acetyl 144.1 0.6 4.4 × 105 0.0003 Cysteine Without CGL L-Cysteine 152.4 1.3 5.8 × 103 0.038 PLP PHF L-Cysteine 28.1 5.3 3.9 × 104 0.014 PHF D,L- 99.3 1.1 8.1 × 105 0.0008 Homocysteine PHF N-Acetyl 339.1 0.7 5.2 × 105 0.0002 Cysteine - Hydrogen sulfide (H2S) is a gaseous transmitter in the blood that acts as a potent anti-oxidant, has anti-inflammatory activity and stimulates NO, thus a target for improving vascular health. In vitro data has shown the H2S activity and previous animal studies with the fullerene have shown benefits in aging.
- Examples of the sulfur-containing compound that serves as the substrate for fullerenes includes, for example, different sulfur-containing amino acids including cysteine, homocysteine, methionine and N-acetyl cysteine. In work conducted during development of embodiments herein, it was shown that PLP (Vitamin B6, which is a co-factor for enzymatic production of H2S) is not necessary for PHF to generate H2S.
- In certain embodiments, the fullerenes described herein are employed with carriers (e.g., particles or devices). Examples of particle matrix carriers include, for example, Polymers: PLGA, PLA, PCL, PEG, Chitosan, alginate, pluronics, lipids and Eudragit; Inorganic: Silica, silicon, titanium dioxide, ceria and amorphous carbon; Metals: Gold, silver and copper; and Eudragit polymers that are either time-dependent release or pH-sensitive and may be preferable for medical food, whereas silica may be preferable for topical application and PEG coated particles for intravenous administration.
- The fullerenes described herein may be used to treat a subject in order to treat a disease or condition. The type of administration is not limited, and could be intravenous, intraocular, topical, etc. In some embodiments, the disease or condition is, for example, heart failure (HF), heart disease (HD), chronic kidney disease, Alzheimer's disease (AD) and peripheral artery disease (PAD).
- In certain embodiments, cardiovascular disease (e.g., heart failure or chronic heart failure) is treated with the fullerenes described herein. In heart failure, it has been shown that hydrogen sulfide is inversely correlated to severity of disease and to poor prognosis.
- Cardiovascular is a brood classification of a disease area that has many different manifestations, including hypertension, dyslipdemia, chronic heart failure, stroke, acute heart failure, angina, atrial fibrillation and peripheral arterial disease. The total cardiovascular market was estimated at ˜$145 billion in 2007, with the majority of the market being attributed to hypertension and dyslipidemia. While these segments have been well served, others such as chronic and acute heart failure remain largely symptomatically treated. The American Heart Association estimates the prevalence of heart failure in the U.S. is estimated near 6 million and analyst expected it to grow to 9 million by 2022. While the disease does occur in all ages, it is predominantly a disease of the elderly and a driver of the expansion due to the aging population. Heart failure the most common cause of hospitalization in the US and total treatment costs continue to rise each year. Heart failure is estimated to account for over $40 billion in total costs and results in almost ½ million deaths annually in the US alone.
- Chronic heart failure is a condition in which the heart can not pump blood adequately and can arise from genetic defect, injury or disease. The inability to deliver blood efficiently to the body leads to shortness of breath, tiredness, and edema (build up of fluids), which further exasperates the shortness of breath and tiredness. The cardiac structural and functional dysfunction that is characterized in heart failure is often defined in terms of the left ventricle ejection fraction (LVEF). On the basis of ejection fraction (EF), heart failure can be classified as with reduced EF (HF-REF) or preserved EF (HF-PEF). Normal EF is usually considered to be above 50%. In patients with reduced EF, the left ventricle (LV) is unable to contract properly and ejects smaller fraction of blood than normal. Patients with preserved EF have normal LVEF but have LV diastolic dysfunction. Usually patients with preserved EF have an increase in LV wall thickness and increased left atrial size.
- The drugs available for treating chronic heart failure are largely enzyme inhibitors or receptor agonists or antagonists which may improve outcome but do not treat the underlying disease. In contrast, hydrogen sulfide prodrugs have been shown in animal studies to improve ventricular function, including ejection fraction and actually reverse disease progression. Although the sales in the over-all cardiovascular markets are declining as the major anti-hypertensive drugs and anti-dyslipidemia drugs are coming off patent, the heart failure market remains exceptionally strong and is predictive to increase significantly over time.
- In certain embodiments, fullerenes are used to generate H2S in vivo to treat alcoholism, opioid withdrawal, or heroin withdrawal. In certain embodiments, fullerene are used to generate H2S in vivo to treat Alzheimer's disease or chronic fatigue syndrome. In certain embodiments, fullerenes are used to generate H2S in vivo to improve social interaction or treat abnormal behavior. In certain embodiments, fullerenes are used to generate H2S in vivo to treat ulcers, airway inflammation, diabetes, obesity, and for causing weight loss. In certain embodiments, fullerenes are used to generate H2S in vivo to treat epilepsy, erectile dysfunction (ED), depression, anxiety, Huntington's disease, high blood pressure, hypertension, colitis, sleep apnea, and Parkinson's disease (PD). In certain embodiments, fullerenes are used to generate H2S in vivo to reduce the severity of neurological injury or prevent stroke. In certain embodiments, fullerenes are used to generate H2S in vivo to treat pulmonary hypertension or prevent renal fibrosis. In certain embodiments, fullerenes are used to generate H2S in vivo to treat gout, a rheumatic disease, skin conditions (including skin disease or cosmetic condition), ocular diseases and osteoarthritis. In some embodiments, fullerenes are used to treat conditions such as hyperhomocysteinemia, homocystinuria, cystinuria, and cystine stones.
- In certain embodiments, the fullerenes described herein is applied locally, such as to the skin, eye, or joint of a subject. For example, for treating and preventing a skin condition (skin disease or cosmetic skin condition) a local application, such as a dermal application, the application is performed at a defined part of the skin (e.g. to a skin area, wherein the skin condition occurs or is expected to occur). The local application may include treating a skin area superficially, intradermally or subcutaneously, i.e. by injection under the skin area of issue. In regard to treating ocular disease, a local application to the ocular tissues may be employed. The local application may include applying the compound for use according to the invention on the ocular surface, e.g. in the form of eye drops, or by injection into the eye. The compound for use according to the invention may be administered as vitreous body substitute or as intraocular implant. In certain embodiments, the fullerenes described herein are used to treat osteoarthritis with a local application to a joint. The compound for use according to the invention may be administered as viscosupplement. A viscosupplement is injected as a gel into the joint of issue, e.g. knee, referred to as intraarticular injection.
- In certain embodiments, the fullerene compositions according to the present technology comprises or consists of a pharmaceutically acceptable carrier, diluent, or excipient (including combinations thereof). Acceptable carriers or diluents for therapeutic use are well known in the pharmaceutical art and are described, for example, in Remington's Pharmaceutical Sciences, Mack Publishing Co. (A. R. Gennaro edit. 1985). The choice of pharmaceutical carrier, excipient, or diluent is selected with regard to the intended route of administration and standard pharmaceutical practice. The pharmaceutical comprise as, or in addition to, the carrier, excipient, or diluent any suitable binder(s), lubricant(s), suspending agent(s), coating agent(s), and/or solubilizing agent(s). This pharmaceutical composition will desirably be provided in a sterile form. It may be provided in unit dosage form and will generally be provided in a sealed container. A plurality of unit dosage forms may be provided.
- Pharmaceutical compositions within the scope of the present technology may include one or more of the following: preserving agents, solubilizing agents, stabilizing agents, wetting agents, emulsifiers, sweeteners, colorants, flavoring agents, odorants, and/or salts. Compounds of the present technology may themselves be provided in the form of a pharmaceutically acceptable salt. In addition, embodiments may comprise buffers, coating agents, antioxidants, suspending agents, adjuvants, excipients, and/or diluents. Examples of preservatives include sodium benzoate, sorbic acid, and esters of p-hydroxybenzoic acid.
- They may also contain other therapeutically active agents in addition to compounds of the present technology. Where two or more therapeutic agents are used they may be administered separately (e.g., at different times and/or via different routes) and therefore do not always need to be present in a single composition. Thus, combination therapy is within the scope of the present technology.
- The routes for administration (delivery) include, but are not limited to, one or more of: oral (e.g. as a tablet, capsule, or as an ingestable solution), topical, mucosal (e.g. as a nasal spray or aerosol for inhalation), nasal, parenteral (e.g. by an injectable form), gastrointestinal, intraspinal, intraperitoneal, intramuscular, intravenous, intrauterine, intraocular, intradermal, intracranial, intratracheal, intravaginal, intracerebroventricular, intracerebral, subcutaneous, ophthalmic (including intravitreal or intracameral), transdermal, rectal, buccal, via the penis, vaginal, epidural, sublingual. It is to be understood that not all of the agent need be administered by the same route. Likewise, if the composition comprises more than one active component, then those components may be administered by different routes.
- If the fullerenes described herein is administered parenterally, then examples of such administration include one or more of: intravenously, intra-arterially, intraperitoneally, intrathecally, intraventricularly, intraurethrally, intrastemally, intracranially, intramuscularly, or subcutaneously administering the agent; and/or by using infusion techniques.
- In some embodiments, pharmaceutical compositions adapted for oral administration are provided as capsules or tablets; as powders or granules; as solutions, food product, syrups or suspensions (in aqueous or non-aqueous liquids); as edible foams or whips; or as emulsions. Tablets or hard gelatin capsules may comprise lactose, maize starch or derivatives thereof, stearic acid or salts thereof. Soft gelatin capsules may comprise vegetable oils, waxes, fats, semi-solid, or liquid polyols etc. Solutions and syrups may comprise water, polyols and sugars. For the preparation of suspensions, oils (e.g., vegetable oils) may be used to provide oil-in-water or water-in-oil suspensions. An active agent intended for oral administration may be coated with or admixed with a material that delays disintegration and/or absorption of the active agent in the gastrointestinal tract (e.g., glyceryl monostearate or glyceryl distearate may be used). Thus, the sustained release of an active agent may be achieved over many hours and, if necessary, the active agent can be protected from being degraded within the stomach. Pharmaceutical compositions for oral administration may be formulated to facilitate release of an active agent at a particular gastrointestinal location due to specific pH or enzymatic conditions.
- Alternatively, the fullerenes described herein may be applied topically in the form of a gel, hydrogel, lotion, solution, cream, ointment or dusting powder. The agent of the present technology may also be dermally or transdermally administered, for example, by the use of a skin patch. For application topically to the skin, the agent of the present technology can be formulated as a suitable ointment containing the active compound suspended or dissolved in, for example, a mixture with one or more of the following: mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene polyoxypropylene compound, emulsifying wax and water. Alternatively, it can be formulated as a suitable lotion or cream, suspended or dissolved in, for example, a mixture of one or more of the following: mineral oil, sorbitan monostearate, a polyethylene glycol, liquid paraffin, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water. If the fullerenes are administered parenterally, then examples of such administration include one or more of intravenously, intra-arterially, intraperitoneally, intrathecally, intraventricularly, intraurethrally, intrasternally, intracranially, intramuscularly or subcutaneously administering the agent; and/or by using infusion techniques.
- Typically, a physician will determine the actual dosage of the fullerenes which will be most suitable for an individual subject. The specific dose level and frequency of dosage for any particular patient may be varied and will depend upon a variety of factors including the activity of the specific compound employed; the metabolic stability and length of action of that compound; the age, body weight, general health, sex, diet, mode and time of administration; rate of excretion; drug combination; the severity of the particular condition; and the individual undergoing therapy. The agent and/or the pharmaceutical composition of the present technology may be administered in accordance with a regimen of from 1 to 10 times per day, such as once or twice per day. For oral and parenteral administration to human patients, the daily dosage level of the agent may be in single or divided doses.
- “Therapeutically effective amount” refers to the amount of the fullerenes describe herein that is effective to achieve its intended purpose (e.g., treating symptoms of an inflammatory disease or other disease or condition described herein). The methods described herein may employ a daily therapeutically effective amount. While individual patient needs may vary, determination of optimal ranges for effective amounts of the compounds related to the technology is within the skill of the art. Generally, the dosage regimen for treating a condition with the compounds and/or compositions of this technology is selected in accordance with a variety of factors, including the type, age, weight, sex, diet and medical condition of the patient; the severity of the dysfunction; the route of administration; pharmacological considerations such as the activity, efficacy, pharmacokinetic and toxicology profiles of the particular compound used; whether a drug delivery system is used; and whether the compound is administered as part of a drug combination and can be adjusted by one skilled in the art. Thus, the dosage regimen actually employed may vary widely and therefore may deviate from the exemplary dosage regimens set forth herein.
- In certain embodiments, the particular molecular structure of a given PHF is varied depending on the type of substrate, temperature, ionic strength, pH and the desired catalysis rate. For example, in general, if higher substrate affinity is desired, then the number of ionic functional groups (e.g., (OH), O or NH) is increased, and if higher catalytic rate is desired, then the number of functional groups is decreased. Further, in work conducted during the development of embodiments herein, it was observed that addition of thiol groups or disulfide groups can significantly increase catalytic activity.
- H2S is produced from cysteine by the enzymes cystathionine β-synthase (CBS) and cystathionine γ-lyase (CGL) in the body. It was discovered that: 1) PHF catalytically produces H2S from cysteine and homocysteine (
FIG. 1A ), and 2) PHF enhances endogenous production of H2S (FIG. 1B ). Further, the catalytic activity depends on the molecular structure of PHF (FIG. 1A ).FIG. 1 shows that polyhydroxy fullerenes (PHF) catalytically produces hydrogen sulfide (H2S). A) PHF stimulates H2S production catalytically in a cell-free chemical reaction involving cysteine and vitamin B6 (PLP) as determined by the lead acetate/lead sulfide method. B) PHF dose—dependently boosts endogenous H2S production in human liver derived (HepG2) cells as determined by an increase in the fluorescence of an H2S detecting chemical probe. Additionally,FIG. 1A shows that polyhydroxy fullerenes (PHF) catalytically produces hydrogen sulfide (H2S) with different PHF formulations MER, SJJR, and JR stimulate H2S production catalytically in a cell free chemical reaction involving cysteine and vitamin B6 as determined by the lead acetate/lead sulfide method (left image) and quantified in the graph to the right. * indicates significant difference (p<0.05) compared to reaction (R×n) mix alone, andFIG. 1B shows PHF dose—dependently boosts endogenous H2S production in human liver derived (HepG2) cells as determined by an increase in the fluorescence of an H2S detecting chemical probe. * indicates significant difference (p<0.05) compared to 0 PHF control group. For MER, SJJR, and JR, used in this example, we used X-ray Photoelectron Spectroscopy (XPS) to estimate their molecular structures. The proposed structures are: i) MER: C60(OH)11O8Na7 (note that the manufacturer says that their PHF is C60(OH)24 and our characterization shows it different); ii) SJJR: C60(OH)10O6Na4; and iii) JR: C60(OH)23O5Na4. - Further work was conducted as follows with regard to the catalytic production of H2S by PHFs. PHF (SJJR; 10 mg/mL) was added to a mixture of L-cysteine (10 mM) and pyridoxal L-phosphate (PLP; 1 mM) in a 96-well plate and then covered with a blotting paper saturated with lead acetate. After 24 hours, the lead acetate paper was removed and scanned. The lead sulfide dots were analyzed for average integrated density using ImageJ. After every 24 hours, the wells were replenished with L-cysteine (10 mM) and covered with the lead acetate paper and the lead sulfide dots were analyzed.
FIG. 2 shows that the H2S production does not decrease with time showing that PHF is not consumed and hence, PHF is a catalyst. - For the experimental work described below, PHFs with general formula of a) C60(OH)tOyMzM′z′ and b) C60(OH)t(SH)uOyMz or C60(OH)t(S)uOyMz, were employed. Examples of a) include: C60(OH)9O7Na6; C60(OH)11O8Na5; C60(OH)11O12Na8; and C60(OH)11O20Na10K6;
- The kinetics and catalysis coefficients for PHF catalyzed H2S production were determined using lead acetate assay (PbA/PbS assay) as generally described in Hine and Mitchell, “Endpoint and Kinetic Measurement of Hydrogen Sulfide Production Capacity in Tissue Extracts” Bio-Protocol, 7 (13), e2382, 2017). Briefly: Reaction mixtures (150 μL/well) containing PHF or enzyme (CGL), enzyme co-factor (PLP) and substrate (e.g., cysteine) were tested in 96-well plates. Immediately after addition of catalyst, 96-well plates were covered with lead acetate saturated paper and placed inside a 37° C. cell culture incubator. At a predetermined time point, the lead acetate paper was removed and scanned, and the lead sulfide dots analyzed with ImageJ using the IntDen function. A calibration curve was prepared with different concentrations of sodium hydrosulfide plotted against the integrated density obtained on lead acetate/lead sulfide paper. The presence of pyruvic acid after reaction was confirmed in a preliminary experiment by liquid chromatography-mass spectroscopy.
- To determine the steady-state kinetic parameters experiments were carried out with different initial substrate concentrations. The initial (linear) slope from the graph of H2S concentration versus time at each substrate concentration was used to determine the reaction velocity, which was plotted against initial cysteine concentrations to obtain Michaelis-Menten curves (
FIGS. 5 and 6 ). Least squares non-linear fitting was used to determine values of Km and Vmax from the equation v=Vmax [S]/(Km+[S]). - Cysteine, by itself under physiological conditions, does not breakdown to produce H2S (
FIG. 4a ). PLP reacts with cysteine slowly to produce H2S (0.024 mM in 24 hours). Addition of PHF to the cysteine-PLP mixture increased H2S production in a concentration dependent manner. Interestingly, H2S production with PHF was observed even in the absence of PLP. H2S production increased with addition of PLP at every concentration of PHF tested. Since H2S generation in both the presence and absence of PLP was highest at 10 mg/mL PHF, further experiments were carried out at this concentration. - In order to investigate the role of PHF in H2S production with cysteine, a multi-day experiment was carried out in which cysteine was added every 24 hours for 17 days. In case PHF is a reactant, the H2S production should decrease with repeated cysteine addition until all PHF is consumed.
FIG. 4b shows that PHF is a catalyst as the amount of H2S produced does not decrease with repeated addition of substrate in presence or absence of PLP. To confirm that the steady H2S production was not due to unreacted cysteine, after 17 days the cysteine addition was stopped and H2S was measured every 24 hours for 4 more days. In presence of PLP all cysteine is reacted in 24 hours and no H2S was detected on days 18-21. In absence of PLP, H2S production decayed with time and no H2S was detected on day 21. - The catalytic activity of PHF is dependent on pH and temperature. Experiments at different pH were carried out in deionized water instead of PBS (
FIG. 4c ). PHF catalytically produced H2S at all pH tested with maximum production aroundpH 7. Addition of PLP enhanced the amount of H2S produced without affecting the trend with pH. - The effect of temperature was determined with reaction taking place in PBS to simulate physiological conditions (
FIG. 4d ). No H2S was produced at 4° C. in the presence or absence of PLP for both PHF and CGL. At room temperature, CGL produced H2S only in presence of PLP. However, with PHF, H2S produced was very low and there was no significant difference between H2S production in presence or absence of PLP. H2S production increased with temperature and the amount of H2S produced was higher in presence of PLP than in absence of PLP at 37, 45 and 60° C. - In presence of PLP, there is a slow increase in reaction velocity at lower cysteine concentrations, suggesting competition of substrate binding with PLP and PHF, as shown in
FIG. 5 . The maximum reaction velocity obtained by non-linear curve fitting is 15.34 (nM)/s and the Michaelis constant (KM) is 35.3 mM. In absence of PLP, reaction velocity increases with cysteine concentration and reaches plateau, which is typical for a catalyst. The maximum reaction velocity with PLP (15.34 nM/s) is higher than in absence of PLP (5.92 nM/s). The KM in absence of PLP (27.3 mM) is lower than in presence of PLP (35.3 mM) corroborating the competitive binding effect. - Interestingly, PHF was able to catalyze breakdown of C—SH bonds in homocysteine and n-acetyl cysteine in presence and absence of PLP. The KM values for homocysteine were higher than cysteine and were highest for n-acetyl cysteine (
FIG. 5C ). Unlike cysteine, the KM values in absence of PLP were higher than with PLP, suggesting that PLP does not bind strongly with homocysteine or n-acetyl cysteine. Similar to KM, the Vmax for homocysteine was smaller than cysteine and smallest for n-acetyl cysteine. No H2S production was observed for methionine as substrate in presence or absence of PLP. This suggests PHF may only cleave terminal thiols. - Polyhydroxy fullerenes can be synthesized with different number of hydroxyl and hemi-ketal groups attached to fullerene cage, which can be determined with XPS C1s spectrum as mono-oxygenated and di-oxygenated carbon, respectively. Different PHF structures were synthesized and their KM and VMax were determined (
FIGS. 6a-d ). The higher the total number of functional groups greater is the production of H2S. Further, with increase in functional groups KM and VMax decreases (FIG. 4e ). The KM value for PHF with highest number of functional group tested (31) was similar to CGL enzyme, however, the VMax for PHF31 was 10 fold higher than CGL enzyme. These results suggest that PHF structure can be modified to obtain desired KM and VMax values. - In vivo experiments were carried out with 12 female CGL knockout mice with results shown in
FIG. 7 . The mice were fed with high-fat diet amended with higher methionine concentration. The first group of mice (n=6) received intraperitoneal injections of PHF (200 μL) three times a week. The second group of mice (n=6) were injected with PBS. The H2S production from CGL enzyme is critical for fat accumulation in adipocytes (fat cells). The CGL knockout mice fed with high fat diet have higher lipid levels in blood (due to their inability to accumulate lipids into fat cells), which is toxic and fatal. The median survival of control (PBS) mice was 11 days (FIG. 7A ). In contrast, PHF catalytically produces H2S that can help in lipid accumulation and increase the median survival to 39 days. PHF's bioavailability is demonstrated by change in color of feces of PHF-injected mice vs control mice (FIG. 7B ). - In vivo experiments were carried out with 10 female C57B1/6 mice. The mice were fed with high-fat/high salt (HFHS) diet. The HFHS diet is expected to induce obesity in mice and reduce their glucose tolerance. The first group of mice (n=5) received intraperitoneal injections of PHF (100 μL) three times a week. The second group of mice (n=5) were injected with PBS. At the beginning of the experiment, 100 g of HFHS food was added to each cage. Every week, the amount remaining was measured and replenished to a total weight of 100 g.
FIG. 8a shows that there was no difference in the amount of food consumed by PHF-treated or control mice over 8 weeks of experiments. Interestingly, the percent change in body weight for PHF-treated mice was lower than control mice (FIG. 8B ). Most importantly, glucose tolerance test suggested that PHF-treated mice have normal glucose tolerance compared to control mice that exhibit diabetic symptoms (FIG. 8C ). - PHF can cleave C—SH bond even when cysteine is part of a peptide (
FIG. 9 ). However, the H2S production volume is 100 times much lower than for free cysteine at similar concentrations. -
- Alves et al., (2011), Eur J Pharmacol 654, 60-67.
- Blackstone et al., (2005), Science 308, 518.
- Elrod et al., (2007), Proc Natl Acad Sci USA 104, 15560-15565.
- Giuliani et al., (2013), Neurobiol Learn Mem 104, 82-91.
- Hine et al. (2015), Cell 160, 132-144.
- Hine et al. (2017), Cell Metab 25, 1320-1333 e1325.
- Huang et al. (2015), Nitric Oxide 46, 192-203.
- Jha et al., (2008), Am J Physiol Heart Circ Physiol 295, H801-806.
- Kovacic et al., (2012), J Card Fail 18, 541-548.
- Liu et al. (2014), Cell Stem Cell 15, 66-78.
- Paul et al., (2014), Nature 509, 96-100.
- Polhemus et al., (2015),
Cardiovasc Ther 33, 216-226. - Sponholz et al. (2016), Eur J Hum Genet 24, 1041-1048.
- Suzuki et al. (2011), Proc Natl Acad Sci USA 108, 13829-13834.
- Szabo, C. (2012), Antioxid Redox Signal 17, 68-80.
- Xue et al. (2013), Antioxid Redox Signal 19, 5-23.
- Yang et al. (2008), Science 322, 587-590.
- Zhang et al., (2013),
Mol Cell Biol 33, 1104-1113. - Zhao et al., (2001), The EMBO journal 20, 6008-6016.
- Zhu et al., (2008), Biochemistry 47, 6226-6232.
- All publications and patents mentioned in the above specification are herein incorporated by reference in their entirety for all purposes. Various modifications and variations of the described compositions, methods, and uses of the technology will be apparent to those skilled in the art without departing from the scope and spirit of the technology as described. Although the technology has been described in connection with specific exemplary embodiments, it should be understood that the technology as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the technology that are obvious to those skilled in pharmacology, biochemistry, medical science, or related fields are intended to be within the scope of the following claims.
Claims (24)
1. A method of treating a subject with a disease or condition comprising: administering a composition comprising fullerenes to said subject with said disease or condition such that H2S is generated in said subject.
2. The method of claim 1 , wherein said disease or condition is associated with inflammation and/or below normal H2S levels in said subject.
3. The method of claim 1 , wherein said administering reduces or eliminates at least one symptom of said disease or condition.
4. The method of claim 1 , wherein said fullerenes comprises polyhydroxy fullerenes.
5. The method of claim 1 , wherein said fullerenes in said composition are all one type of fullerene.
6. The method of claim 1 , wherein said fullerenes in said composition are two or more types of fullerenes.
7. The method of claim 1 , wherein said fullerenes in said composition are all one type of fullerene selected from the group consisting of: C60(OH)9O7Na6; C60(OH)11O8Na5; C60(OH)11O12Na8; C60(OH)11O20Na10K6; C60(OH)6O4Na4; C60(OH)20O8Na4; C60(OH)10O13Na6; C60(OH)4O14Na17; C60(OH)13O4Na3; C60(OH)10; C60(OH)22-24; C60(OH)36; C60(OH)44; C60O13Na14; Gd@C82(OH)15O12Na5; Gd3N@C80(OH)13O9Na6; C60(OH)11O8S8Na5; C60(OH)11(SH)5O8Na5; C60C12N4H24; and C60C12N6H30O12.
8. The method of claim 1 , wherein said fullerenes in said composition are two or more types of fullerenes selected from the group consisting of: C60(OH)9O7Na6; C60(OH)11O8Na5; C60(OH)11O12Na8; C60(OH)11O20Na10K6; C60(OH)6O4Na4; C60(OH)20O8Na4; C60(OH)10O13Na6; C60(OH)4O14Na17; C60(OH)13O4Na3; C60(OH)10; C60(OH)22-24; C60(OH)36; C60(OH)44; C60O13Na14; Gd@C82(OH)15O12Na5; Gd3N@C80(OH)13O9Na6; C60(OH)11O8S8Na5; C60(OH)11(SH)5O8Na5; C60C12N4H24; and C60C12N6H30O12.
9. The method of claim 1 , wherein said fullerenes are one or more compounds according to the formula C2n(OH)t(SH)u(NH2)v(COOH)w(COOM)xOyMz, wherein M is an alkali metal, alkaline earth metal, transition metal, post-transition metal, lanthanide or actinide, n is a number ranging from 10 to 270; and t, u, v, w, x, y and z can range from 0 to the total number of carbon atoms present in the cage.
10. The method of claim 1 , wherein said composition comprises a food product.
11. The method of claim 6 , wherein said food product comprises carbohydrates, proteins, and fats.
12. The method of claim 10 , wherein said food product is in a form selected from the group consisting of: mayonnaise, margarine, low fat spread, yoghurt, a fruit smoothie, a protein smoothie, a cheese spread, processed cheese, a dairy dessert, a flavored milk, cream, a fermented milk product, cheese, butter, a condensed milk product, an ice cream mix, a soy product, pasteurized liquid egg, a bakery product, a confectionary product, confectionary bar, chocolate bar, high fat bar, energy bar, liquid emulsion, powder, spray dried powder, freeze dried powder, pudding, a gel, a gel concentrate, a liquid drink, and jelly.
13. A method comprising: contacting a sulfur-containing compound or thiol-containing compound, with a composition comprising fullerenes in vitro such that H2S is generated.
14. The method of claim 13 , further comprising capturing at least some of said H2S that is generated.
15. The method of claim 13 , wherein said fullerenes in said composition are all one type of fullerene.
16. The method of claim 13 , wherein said fullerenes in said composition are two or more types of fullerenes.
17. A composition or article of manufacture comprising: a food product, wherein said food product comprises a composition comprising fullerenes.
18. The composition or article of manufacture of claim 17 , wherein said food product comprises carbohydrates, proteins, and fats.
19. The composition or article of manufacture of claim 17 , wherein said food product is in a form selected from the group consisting of: mayonnaise, margarine, low fat spread, yoghurt, a fruit smoothie, a protein smoothie, a cheese spread, processed cheese, a dairy dessert, a flavored milk, cream, a fermented milk product, cheese, butter, a condensed milk product, an ice cream mix, a soy product, pasteurized liquid egg, a bakery product, a confectionary product, confectionary bar, chocolate bar, high fat bar, energy bar, liquid emulsion, powder, spray dried powder, freeze dried powder, pudding, a gel, a gel concentrate, a liquid drink, and jelly.
20. The composition or article of manufacture of claim 17 , wherein said fullerenes in the food product comprise polyhydroxy fullerenes.
21. The composition or article of manufacture of claim 17 , wherein said fullerenes in said food product are all one type of fullerene.
22. The composition or article of manufacture of claim 17 , wherein said fullerenes in said food production are two or more types of fullerenes.
23. The composition or article of manufacture of claim 17 , wherein said fullerenes in said food product are all one type of fullerene selected from the group consisting of: C60(OH)9O7Na6; C60(OH)11O8Na5; C60(OH)11O12Na8; C60(OH)11O20Na10K6; C60(OH)6O4Na4; C60(OH)20O8Na4; C60(OH)10O13Na6; C60(OH)4O14Na17; C60(OH)13O4Na3; C60(OH)10; C60(OH)22-24; C60(OH)36; C60(OH)44; C60O13Na14; Gd@C82(OH)15O12Na5; Gd3N@C80(OH)13O9Na6; C60(OH)11O8S8Na5; C60(OH)11(SH)5O8Na5; C60C12N4H24; and C60C12N6H30O12.
24. The composition or article of manufacture of claim 23 , wherein said fullerenes in said food product are two or more types of fullerenes selected from the group consisting of: C60(OH)9O7Na6; C60(OH)11O8Na5; C60(OH)11O12Na8; C60(OH)11O20Na10K6; C60(OH)6O4Na4; C60(OH)20O8Na4; C60(OH)10O13Na6; C60(OH)4O14Na17; C60(OH)13O4Na3; C60(OH)10; C60(OH)22-24; C60(OH)36; C60(OH)44; C60O13Na14; Gd@C82(OH)15O12Na5; Gd3N@C80(OH)13O9Na6; C60(OH)11O8S8Na5; C60(OH)11(SH)5O8Na5; C60C12N4H24; and C60C12N6H30O12.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/277,099 US20210378982A1 (en) | 2018-09-24 | 2019-09-24 | Fullerenes to treat diseases and conditions |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862735621P | 2018-09-24 | 2018-09-24 | |
US17/277,099 US20210378982A1 (en) | 2018-09-24 | 2019-09-24 | Fullerenes to treat diseases and conditions |
PCT/US2019/052682 WO2020068817A1 (en) | 2018-09-24 | 2019-09-24 | Fullerenes to treat diseases and conditions |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2019/052682 A-371-Of-International WO2020068817A1 (en) | 2018-09-24 | 2019-09-24 | Fullerenes to treat diseases and conditions |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US18/409,328 Division US20240139121A1 (en) | 2018-09-24 | 2024-01-10 | Fullerenes to treat diseases and conditions |
Publications (1)
Publication Number | Publication Date |
---|---|
US20210378982A1 true US20210378982A1 (en) | 2021-12-09 |
Family
ID=69949747
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/277,099 Abandoned US20210378982A1 (en) | 2018-09-24 | 2019-09-24 | Fullerenes to treat diseases and conditions |
US18/409,328 Pending US20240139121A1 (en) | 2018-09-24 | 2024-01-10 | Fullerenes to treat diseases and conditions |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US18/409,328 Pending US20240139121A1 (en) | 2018-09-24 | 2024-01-10 | Fullerenes to treat diseases and conditions |
Country Status (2)
Country | Link |
---|---|
US (2) | US20210378982A1 (en) |
WO (1) | WO2020068817A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4301463A1 (en) * | 2021-03-01 | 2024-01-10 | Pharmzandia Corporation | Fullerene gaba dopa and methods |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9567439B1 (en) * | 2011-08-11 | 2017-02-14 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Sulfur composites and polymeric materials from elemental sulfur |
WO2018033033A1 (en) * | 2016-08-15 | 2018-02-22 | 北京福纳康生物技术有限公司 | Use of fullerene structure in preparation of medicament for treating anemia and complication thereof |
CN108497099A (en) * | 2018-03-27 | 2018-09-07 | 厦门福慈生物科技有限公司 | Fullerene be used to be prepared into the purposes of fullerene microcapsule powder |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5648523A (en) * | 1995-10-26 | 1997-07-15 | Chiang Long Y | Fullerene derivatives as free-radical scavengers |
JP2001122606A (en) * | 1999-10-22 | 2001-05-08 | Fuairudo Kk | Method for production of fullerene water and device therefor |
US8182830B2 (en) * | 2010-01-05 | 2012-05-22 | Medtronic Vascular, Inc. | Hydrogen sulfide generating polymers |
GB201121519D0 (en) * | 2011-12-14 | 2012-01-25 | Ip Science Ltd | Fat-based food products |
EP3094316A4 (en) * | 2014-01-13 | 2017-07-05 | University of Central Florida Research Foundation, Inc. | Fullerene compounds as antioxidant therapy |
WO2019184419A1 (en) * | 2018-03-27 | 2019-10-03 | 厦门福慈生物科技有限公司 | Use of fullerene compound, fullerene microcapsule powder and preparation method and application thereof |
-
2019
- 2019-09-24 WO PCT/US2019/052682 patent/WO2020068817A1/en active Application Filing
- 2019-09-24 US US17/277,099 patent/US20210378982A1/en not_active Abandoned
-
2024
- 2024-01-10 US US18/409,328 patent/US20240139121A1/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9567439B1 (en) * | 2011-08-11 | 2017-02-14 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Sulfur composites and polymeric materials from elemental sulfur |
WO2018033033A1 (en) * | 2016-08-15 | 2018-02-22 | 北京福纳康生物技术有限公司 | Use of fullerene structure in preparation of medicament for treating anemia and complication thereof |
CN108497099A (en) * | 2018-03-27 | 2018-09-07 | 厦门福慈生物科技有限公司 | Fullerene be used to be prepared into the purposes of fullerene microcapsule powder |
Non-Patent Citations (2)
Title |
---|
Cai et al., "Polyhydroxylated Fullerene Derivative C60(OH)24 Prevents Mitochondrial Dysfunction and Oxidative Damage in an MPP+-Induced Cellular Model of Parkinson's Disease", 2008, Journal of Neuroscience Research, 86, pgs. 3622-3634 (Year: 2008) * |
Nie et al., "Fullerenol inhibits the cross-talk between bone marrow-derived mesenchymal stem cells and tumor cells by regulating MAPK signaling", 2017, Nanomedicine: Nanotechnology, Biology, and Medicine, 13, pgs. 1879-1890 (Year: 2017) * |
Also Published As
Publication number | Publication date |
---|---|
US20240139121A1 (en) | 2024-05-02 |
WO2020068817A1 (en) | 2020-04-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20240139121A1 (en) | Fullerenes to treat diseases and conditions | |
JP6533519B2 (en) | Lipid capture in RAS cancer | |
ES2640777T3 (en) | Anaplerotic therapy for Alzheimer's disease | |
US20050090553A1 (en) | Compositions and method for treatment of chronic inflammatory diseases | |
CN104998264A (en) | Method and composition for treating mammalian diseases and injuries caused by the over-expression of peroxynitrite | |
Swenson | Respiratory and renal roles of carbonic anhydrase in gas exchange and acid-base regulation | |
WO2022060397A1 (en) | Method and composition for the reduction of viral replication, duration and spread of the covid-19 and the flu | |
US20220062203A1 (en) | N-Acetylcysteine Amide (NACA) and (2R,2R')-3,3' disulfanediyl BIS(2-Acetamidopropanamide) (DINACA) for the Prevention and Treatment of Radiation Pneumonitis and Treatment of Pulmonary Function in Cystic Fibrosis | |
WO2017100266A1 (en) | Glycolate oxidase inhibitors and methods of use for the treatment of kidney stones | |
JP2014132017A (en) | Composition and its use | |
EP3980000A1 (en) | Methods and compositions for altering senescence associated secretory phenotype | |
JP2021152087A (en) | Ado-resistant cysteamine analogs and uses thereof | |
AU2024200658A1 (en) | Capric acid and myristic acid compositions for treating conditions | |
US20070218126A1 (en) | Compositions and Methods for Reducing Inflammation and Pain Associated with Acidosis | |
JP2010522146A (en) | Use of citrulline to prevent increased protein carbonylation and to treat lesions caused thereby | |
TW201605434A (en) | Use of cysteamine and derivatives thereof to treat mitochondrial diseases | |
US20220249438A1 (en) | Carbocyanine compounds for targeting mitochondria and eradicating cancer stem cells | |
ES2260414T3 (en) | REGULATING AGENTS OF THE AUTONOMOUS SYSTEM AND DIETETIC FOOD AND DRINKS. | |
JP2005516996A (en) | Compositions and methods for promoting lipid mobilization, glycogen mobilization, or both in humans | |
JP2009501795A (en) | Compositions and methods for the treatment and prevention of health conditions associated with hyperuricemia | |
US20080161318A1 (en) | Novel compositions and uses thereof | |
US20140018426A1 (en) | Food or beverage composition fortified with thyronamines and/or thyronamine precursors | |
MX2011010077A (en) | Composition for regulating autonomic nervous activity and method for regulating autonomic nerve. | |
Zhang et al. | Potential nutritional healthy-aging strategy: enhanced protein metabolism by balancing branched-chain amino acids in a finishing pig model | |
EP2844277B1 (en) | Diamine oxidase for use in the treatment or prevention of attention deficit hyperactivity disorder (adhd) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: APPLICATION UNDERGOING PREEXAM PROCESSING |
|
AS | Assignment |
Owner name: THE CLEVELAND CLINIC FOUNDATION, OHIO Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KRISHNA, VIJAY;HINE, CHRISTOPHER;REEL/FRAME:055939/0469 Effective date: 20180928 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: EXPRESSLY ABANDONED -- DURING EXAMINATION |